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ABSTRACT 
In the context of health care, information technology (IT) has an important role in the 
operational infrastructure, ranging from business management to patient care. An 
essential part of the system is medication management in inpatient and outpatient care. 
Community pharmacists‟ strategy has been to extend practice responsibilities beyond 
dispensing towards patient care services. Few studies have evaluated the strategic 
development of IT systems to support this vision.  
 
The objectives of this study were 1) to assess and compare independent Finnish 
community pharmacy owners‟ and staff pharmacists‟ priorities concerning the content and 
structure of the next generation of community pharmacy IT systems, 2) to explore 
international experts‟ visions and strategic views on IT development needs in relation to 
services provided in community pharmacies, 3) to identify IT innovations facilitating 
patient care services and to evaluate their development and implementation processes, 
and 4) to assess community pharmacists‟ readiness to adopt innovations.  
 
This study triangulated qualitative and quantitative data collected by a qualitative 
personal interview of 14 experts in community pharmacy services and related IT from 
eight countries; a national survey of Finnish community pharmacy owners (mail survey, 
response rate 53%, n=308), and of a representative sample of staff pharmacists (online 
survey, response rate 22%, n=373). 
 
Finnish independent community pharmacy owners gave priority to logistical functions but 
also to those related to medication information and patient care. The managers and staff 
pharmacists have different views of the importance of IT features, reflecting their different 
professional duties in the community pharmacy. This indicates the need for involving 
different occupation groups in planning the new IT systems for community pharmacies. A 
majority of the international experts shared the vision of community pharmacy adopting a 
patient care orientation; supported by IT-based documentation, new technological 
solutions, access to information, and shared patient data. Opportunities to achieve this 
vision included IT technology, professional skills, and inter-professional collaboration. 
Threats associated with implementing this vision included high costs, pharmacists‟ 
attitudes, and the absence of acceptable IT solutions. Community pharmacy IT 
innovations were rare, which is paradoxical because owners‟ and staff pharmacists‟ 
perception of their innovativeness was seen as being high. Community pharmacy IT 
systems development processes usually had not undergone systematic needs 
assessment research beforehand or evaluation after the implementation and were most 
often coordinated by national governments without subsequent commercialization. 
Specifically, community pharmacy IT developments lack research, organization, 
leadership and user involvement in the process.  
 
Those responsible for IT development in the community pharmacy sector should create 
long-term IT development strategies that are in line with community pharmacy service 
development strategies. This could provide systematic guidance for future projects 1) to 
ensure that potential innovations are based on a sufficient understanding of pharmacy 
practice problems that they are intended to solve, and 2) to encourage strong leadership 
in research, development of innovations so that community pharmacists‟ potential 
innovativeness is used, and that professional needs and strategic priorities will be 
considered even if the development process is led by those outside the profession.  
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DEFINITIONS OF THE KEY CONCEPTS 
 
Community Pharmacy 
Community pharmacy is a health care unit which is responsible for acquiring and 
distributing drug products to patients and for providing pharmaceutical services 
which include evidence-based guidance of drug therapy and health promotion in 
order to achieve rational use of medicines (Medicines Act 395/1987). The 
obligations set for a community pharmacy vary in different countries.   
 
Diffusion of innovations 
Rogers (2003) defines diffusion as the communication process of the innovation 
to an individual‟s or to a social system‟s use. In this process individuals create and 
share information about the new innovation in order to reach an understanding of 
it, which happens through certain channels and within a certain timeframe.   
 
Extranet 
Extranet as a computer network allowing controlled access from the outside, but 
is not accessible to the general public. Extranet is usually used for specific 
business or educational purposes for professional groups, suppliers or partners 
(BusinessDictionary 2011). 
 
Generation of Innovations 
Generation of Innovations consists of six phases, usually beginning with the 1) 
Problem or Need; 2) Research; 3) Development; 4) Commercialization; 5) 
Diffusion and Adoption; 6) Consequences (Rogers 2003). 
 
Information technology 
Information Technology (IT) is defined by the Information Technology Association 
of America (ITAA) and the International Foundation for the Information 
Technology (IF4IT) as the "technology" used for the study, understanding, 
planning, design, construction, testing, distribution, support and operations of 
  
software, computers and computer-related systems that exist for the purpose of 
data, information and knowledge processing. 
 
Innovation 
The widely used Rogers‟ (2003) theory on Diffusion of Innovations defines 
innovation as a “new idea, practice or object perceived by a person or unit”. 
 
Internet 
The internet is a global system of interconnected computer networks that use the 
standard Internet Protocol Suite (TCP/IP) to serve billions of users worldwide 
(Wood and Smith 2005).  
 
Intranet 
Intranet is a network of documents that is identical in appearance and function to 
the World Wide Web, but is closed off from the general Internet by a firewall, so 
that the documents are accessible only within a defined local network 
(BusinessDictionary 2011). 
 
Logistics 
Logistics is the management of material, service, information and capital flow 
(LogisticsWorld 2011). In this study‟s framework the logistics means stock 
management in the community pharmacy context.  
 
Management 
The verb manage comes from Italian maneggiare (to handle – especially tools), 
which in turn derives from the Latin manus (hand). Nowadays management can 
be defined as the act of getting people together to accomplish desired goals using 
available resources efficiently and effectively, including planning, organizing, 
staffing, leading or directing, and controlling an organization (a group of one or 
more people or entities). Resourcing encompasses the deployment and 
manipulation of human, financial and technological resources.  
 
 
  
Medication management 
Medication management means planned system of processes and behaviours 
which determine how medicines are used by patients (Shaw et al. 2002). The 
focus is on the appropriate and safe use of medicines and on prevention of 
medication errors (NCC MERP 2005). There are many aspects related, such as 
getting the right drug at the right time to the right patient, avoiding potentially 
harmful drugs, drug-drug interactions and adverse reactions. Monitoring of 
medications is especially important for patients taking numbers of medications or 
patients with chronic illnesses and multiple diseases, which is common among 
elder people.   
 
Medication management services 
Medication management services mean the processes for designing, 
implementing, delivering and monitoring patient-focused pharmacotherapy. The 
services can cover all aspects of the supply and therapeutic use of medicines, 
from individual patient level to an organizational level (Shaw et al. 2002, Agency 
for Health Care Research and Quality 2011).  
 
Medication Therapy Management (MTM) 
Medication Therapy Management is a distinct service or group of services that 
optimize therapeutic outcomes for individual patients (The American Pharmacists 
Association 2004). MTM services are ”provided by licensed pharmacists, as a 
collaborative, multidisciplinary, inter-professional approach to the treatment of 
chronic diseases for targeted individuals, to improve the quality of care and 
reduce overall cost in the treatment of such diseases” (Compilation of Patient 
Protection and Affordable Care Act 2010). Medication Therapy Management 
Services are independent of, but can occur in conjunction with, the provision of a 
medication product.  
 
Patient care 
“Pharmacists provide patient care that optimizes medication therapy and 
promotes health, wellness, and disease prevention. The practice of clinical 
pharmacy embraces the philosophy of pharmaceutical care; it blends a caring 
  
orientation with specialized therapeutic knowledge, experience, and judgment for 
the purpose of ensuring optimal patient outcomes” (American College of Clinical 
Pharmacy 2008).  
 
Pharmaceutical care 
Pharmaceutical care is “a patient-centered practice in which the practitioner 
assumes responsibility for a patient‟s drug-related needs and is held accountable 
for this commitment” (Cipolle et al. 2004). The professional orientation started in 
1990 with the discussion of the philosophy by Hepler and Strand in 1990. The 
evolution of the professional philosophy and practice is discussed in Chapter 2. 
Since early 1990s, community pharmacies worldwide have been urged to adopt 
pharmaceutical care in their practices (Hepler and Strand 1990, FIP 1997, 
Christensen and Farris 2006, Hughes et al. 2010).  
 
Policy 
Policy means a principle, plan, or course of action, as pursued by a government, 
organization, or individual (Webster‟s New World College Dictionary 2011) 
intended to influence and determine decisions and actions. A policy is a broad 
framework that shapes thinking and guides long-term decision-making. A national 
drug policy defines and sets medium and long-term goals for the pharmaceutical 
sector and sets up the strategies to reach the goals (WHO 2001, Väänänen 
2008). 
 
Social media 
Social media is collections of Web- and mobile-based applications that allow 
individuals “to 1) construct a public or semi-public profile within a bounded 
system, 2) articulate a list of other users with whom they share a connection, and 
3) view and traverse their list of connections and those made by others within the 
system.” (Boyd and Ellison 2008). 
 
Strategy 
The term strategy (Greek στρατηγός, [strategos]) was originally used in the 
military and it concerned  deciding the means used to achieve a specific goal in 
  
the war. A strategy is concerned with the actions and resources needed to 
achieve specific long-term objectives. Strategy is a bridge between the vision and 
policy, and concrete operational outcomes. 
 
Vision 
Vision is an ability through mental activity to perceive something that is not visible 
and to develope a strategy to make it a reality in the future. An organization or 
profession would like to achieve the vision in the mid-term or long-term future 
(BusinessDictionary 2011). 
 
Web 2.0 
Web 2.0 technologies focus on connecting people by characteristics of user-
generated content, openness and networking effects (O‟Reilly 2008). 
  
ABBREVIATIONS 
AACP The American Association of Colleges of Pharmacy (US) 
ADR  Adverse drug reaction 
AFP  The Association of Finnish Pharmacies 
APhA The American Pharmacists Association (US) 
ASHP The American Society of Health-System Pharmacists, previously the 
American Society of Hospital Pharmacists (US) 
CMR Comprehensive Medication Review (Finland) 
CDSS Clinical Decision Support System 
CPOE Computerized physician order entry (US) 
DDI  Drug-drug interaction 
DMMR The Domiciliary Medication Management Review (Australia) 
DRP  Drug-related problem 
DUR  Drug Utilization Review (US) 
eGK  Elektronische Gesundheitskarte (Electronic health card in German)  
eHC  Elektronic Health Card (Germany) 
ECHO Economic, Clinical and Humanistic Outcomes 
ECJ  The European Court of Justice 
EHR  Electronic health record 
EMR  Electronic medication record 
E-MAIL Electronic mail 
EU  European Union  
ePHR Electronic personal health record 
FIP  International Pharmaceutical Federation 
GP  General Practitioner 
GPP  Good Pharmacy Practice 
HIMMS The Healthcare Information and Management Systems Society 
HIT  Health information technology 
HHS  Department of Health and Human Services (US) 
HMR Home Medicines Review (Australia) 
HRQOL Health-related quality of life 
IF4IT International Foundation for Information Technology 
  
IT  Information technology 
ITAA  Information Technology Association of America (US) 
ITDM IT-enabled diabetes management (US) 
MAP  Medication-related action plan 
MTM Medication Therapy Management (US) 
MTR  Medication Therapy Review (US) 
MTMS Medication Therapy Management Services (US)  
NEHTA The National eHealth Transition Authority (Australia) 
NL The Netherlands 
NHS The National Health Service (UK) 
OBRA‟90 Omnibus Budget Reconciliation Act of 1990 (US) 
ONC The Office of the National Coordinator for Health Information 
Technology (US) 
OTC  Over-The-Counter 
PCNE Pharmaceutical Care Network Europe 
PG  The Pharmacy Guild of Australia 
PMR  Personal medication record 
PWDT Pharmacist‟s Workup of Drug Therapy 
RSS  Really Simple Syndication 
RxHub  The National Patient Health Information Network™ (US) 
SPSS Statistical Package for the Social Sciences 
SWOT Strenghts, Weaknesses, Opportunities and Threats 
UK  United Kingdom of Great Britain and Northern Ireland 
US  United States of America 
USP  The United States Pharmacopeia 
WHO World Health Organization 
WWW  World Wide Web 
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1 INTRODUCTION 
"I am providing pharmaceutical care, what should my technology be doing"  
IT-expert interviewed 
 
Community pharmacies are an essential part of health care and have a role in 
promoting public health. It is expected by the societies that pharmacists work as 
members of the health care team and promote health by assuring safe, 
appropriate and economic use of medications (Medicines Act 395/1987, Ministry 
of Social Affairs and Health 2007, Council of Europe 2007, Ministry of Social 
Affairs and Health 2011). Since the 1990 publication of Hepler and Strand‟s 
landmark vision of pharmacists‟ involvement in patient care (Hepler and Strand 
1990), community pharmacies have been urged to adopt patient care services and 
pharmaceutical care in their practices. The pharmacy profession worldwide has 
made patient-oriented services its long-term strategic priority (FIP 1997, 
Christensen and Farris 2006, WHO 2006, Palmer et al. 2007, Hughes et al. 2010). 
Community pharmacies have a special responsibility for assuring appropriate and 
safe pharmacotherapy for the patients in outpatient care.  
 
Information technology (IT) is increasingly important in health care. Health 
Information Technology (HIT) is a broad array of technologies used in managing 
and sharing health information electronically (Jamal et al. 2009). It is regarded as 
a tool for improving quality, safety and efficiency of health systems (Chaudry et al. 
2006). Medication management systems are an example of this technology.  An 
optimum community pharmacy IT system should 1) support business 
management and administration; 2) support dispensing and reimbursement 
routines, and 3) facilitate medication management by supporting new cognitive 
pharmaceutical services. Innovative solutions are needed to support the 
infrastructure for these services, but they must be feasible also in a business 
sense. The development of such IT systems is subject  to significant constraints, 
such as the needs to manage the logistics of product selection, procurement and 
dispensing; to facilitate communication within the pharmacy; and to integrate 
 20 
 
functionalities with other health care service providers (e.g., through sharing 
patient information).  
 
Due to the lowering prices of medicines, community pharmacies are forced to 
seek enhanced productivity and cost-effectiveness in their routine operations. At 
the same time, they are expected to innovate and implement new professional 
patient care services. These new services are expected to improve appropriate 
use of medications and these demands are increasingly set by the society 
(Ministry of Social Affairs and Health 2011). Consequently, the availability of 
suitable IT programs can be a key factor in determining the direction that the 
professional practice will take within community pharmacies. However, the IT is 
not an intrinsic value, but an important tool and facilitator for a pharmacist in 
pharmaceutical service provision. When the features of the IT systems do not 
support the provision of cognitive pharmaceutical services, it is difficult for 
pharmacists to develop their professional role with regard to the provision of 
patient care. Thus, achieving the pharmacy profession‟s strategic goals requires 
new functionalities for community pharmacies‟ IT systems.  
 
Despite the importance of patient care services and the existence of a vast body 
of literature on them, there have been few studies evaluating experiences with IT 
systems in community pharmacies. Particularly, a holistic view has been missing. 
Instead, the existing literature primarily focuses on the software required for 
discrete functions, such as  electronic prescribing (Bates et al. 1998, Bates et al. 
1999, Mekhjian et al. 2002, Spencer et al. 2005, Grossman et al. 2007, Donyai et 
al. 2008), procedures for drug utilization review (DUR) (Armstrong and Markson 
1997, Lyles et al. 1998, Monane et al. 1998, Chui and Rupp 2000, Chrischilles et 
al. 2002, Bluml 2005), and medication therapy management (MTM) (American 
Pharmacists Association and the National Association of Chain Drug Stores 
Foundation 2008, Bluml 2005, The Lewin Group 2005, Mc Givney et al. 2007, 
Barnett et al. 2009, Klimek 2009). Most service implementation studies have 
focussed on assessing facilitators and barriers to change and its management 
(Roberts et al. 2005, Palmer et al. 2007, Roberts et al. 2008, Gastelurrutia et al. 
2009). Few studies have taken a broader view on the strategic and long-term 
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development of IT systems. One of the few events having a long-term strategic 
focus was  an expert conference organized by the United States Pharmacopeia 
(USP) in 1992 to identify a vision for the future of the pharmacy by 2020 (Bezolt et 
al. 1993). At that time, the three most important factors affecting the future of the 
community pharmacy were considered to be: the market change from local to 
global; achieving cost-effectiveness in the health care; and the benefits brought by 
IT. Even though IT was identified among the three most important factors 
determining the community pharmacy systems‟ future already in the early 1990s, 
little discussion has followed about the strategic importance of IT in service 
provision support and financial management of community pharmacies. The goal 
of this thesis is to examine this gap in the literature.  
 
The literature review of the thesis describes a conceptual, theoretical and 
contextual framework of the study (Chapters 2-6). The search strategy for this 
literature review was to identify studies related to patient care in the community 
pharmacy context and information technology supporting medication management 
in community pharmacies. To search for this data, electronic database PubMed 
was used. Additional strategies included searching bibliographies of eligible 
studies, a handsearch of the medicines informatics journals, as well as documents 
and statements established by international and national organizations. The 
connections and a complete view with all aspects related in this research area are 
presented in Figure 1.  
 
The theoretical basis for this thesis was the professional philosophy of 
pharmaceutical care. Chapter 2 describes the evolution of this professional 
philosophy into practice and the desired role change of the pharmacists through 
the provision of services. The IT applications needed to support medication 
management and patient care services in community pharmacies are discussed in 
Chapter 3. Included in this discussion are:  1) Electronic Health Records, including 
electronic prescribing and clinical decision support systems; 2) Health Information 
Technology in medication management; and 3) Internet as a facilitator of new 
patient care services in community pharmacies. 
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The empirical part of this thesis focuses on community pharmacy IT development 
needs to support patient care service provision. International and national 
perspectives were examined in this respect. For the strategic analysis of the 
current status of IT systems a SWOT analysis method developed by Albert 
Humphrey in 1960s–1970s was applied. The SWOT method is designed to 
identify strengths, weaknesses, opportunities and threats in the current action. 
Rogers‟ theory on Diffusion of Innovations was applied as achievements in 
community pharmacy IT development were considered to be innovations (Chapter 
4). The thesis also reviews the Finnish pharmacy system and IT development in 
the community pharmacy context from the strategic perspective (Chapter 5).  
  
 23 
 
 
Figure 1 Illustration of areas where information technology can support patient care in 
the community pharmacy context. 
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2 PHARMACEUTICAL CARE  
 
The traditional role of the community pharmacist has been compounding, 
packaging and dispensing medications. Technological change and development 
of drug industry have been changing this role. Increasing use of medications has 
brought new challenges in terms of inappropriate and unsafe use of medicines 
(Hepler and Strand 1990). According to the early definition, quality assurance with 
regard to pharmacotherapy is based on identifying, resolving and preventing drug-
related problems (DRPs). The goal of optimum pharmacotherapy can be achieved 
by ensuring definite clinical outcomes that can vary depending on the disease and 
its status as well as patient and medication. Thus, the goal can be: 1) Curing a 
disease; 2) Elimination or reduction of patient‟s symptoms; 3) Arresting or slowing 
a disease process; and 4) Preventing a disease or symptoms (Hepler 1996). The 
debate has emphasized the responsibility of pharmacy profession in patient‟s 
care, which has led to the evolution of a professional philosophy and practice 
known as “pharmaceutical care” (Hepler and Strand 1990, Berenguer et al. 2004). 
An updated definition of pharmaceutical care is “a patient-centered practice in 
which the practitioner assumes responsibility for a patient‟s drug-related needs 
and is held accountable for this commitment” (Cipolle et al. 2004). The focus is on 
the whole patient, drug therapy use, and the recognition of a specific patient‟s 
individual drug therapy needs (McGivney et al. 2007).  
 
It is evident that community pharmacist‟s involvement in this kind of quality 
assurance functions will require close collaboration with the patients and other 
health care providers, particularly prescribers. Since the international launch of 
the pharmaceutical care philosophy in 1990 (Hepler and Strand), the role of the 
pharmacists in pharmaceutical care has been expanding (Nkansah et al. 2010). 
According to evidence, pharmacists are cooperating more with patients and other 
health care professionals to identify, prevent, and resolve drug-related problems, 
promote rational prescribing and health education (Nkansah et al. 2010). The 
change process can be seen as an innovation diffusion process of implementing 
the professional philosophy into practice. The importance and impact of 
 25 
 
pharmaceutical care in the entire health care system and society must be 
addressed through evidence, which has been cumulating quite slowly (Nkansah et 
al. 2010). Examples of practice-management barriers prohibiting the widespread 
adoption and implementation of pharmaceutical care practices in the community 
have been reported to be: community pharmacies‟s physical organization and 
workflow, the shortage of pharmacies and other resources, and the lack of a 
standard payment mechanism for services and training (McGivney et al. 2007).  
Finding strategies and tools for dealing with these challenges is a professional 
and policy issue involving the entire health care sector. 
2.1 Evolution of pharmaceutical care 
 
This Chapter is primarily based on two sources:  a review article by Berenguer et 
al. (2004), and a Danish doctoral thesis by Rossing (2003). These sources were 
used because of they cover the entire development of the philosophy of 
pharmaceutical care. The information of these two sources has been updated by 
a literature search in 2010–2011. The evolution and launch of the pharmaceutical 
care philosophy and practice is presented in Table 1 and described in more detail 
in Chapters 2.1.1 and 2.1.2. The first Chapter (2.1.1) describes the evolution of 
pharmaceutical care in the United States (US), because the entire philosophy 
originates from there as an extension of clinical pharmacy in hospitals. The other 
Chapter (2.1.2) briefly describes the landmarks of the international launch of 
pharmaceutical care, with the special emphasis on developments in Europe and 
initiatives taken by international organizations to promote its implementation.  
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Table 1 Landmarks in early phase evolution of Pharmaceutical Care as a professional 
philosophy (based on Rossing 2003, Berenguer et al. 2004). 
Year Landmark Reference 
1960- Clinical pharmacy in hospital setting (US) Angaran et al. 1988 
1975 Millis Report (US) Millis 1975 
Clinical aspects: rational and safe use of medicines Mikael et al. 1975 
1979 Standards for Good Pharmaceutical Practice (US) Brodie 1980 
1984 Conference: Pharmacy in the 21st Century 
organized by American Association of Colleges of 
Pharmacy (AACP) 
 
1985 Hilton Head Conference organized by ASHP (US) Hepler 1985 
1987 Relationship between the patient and the 
pharmacist: patient‟s awareness and commitment 
to the drug therapy (US) 
Hepler 1987 
1988 Pharmacist‟s Workup of Drug Therapy (PWDT), 
(US) 
Strand et al. 1988 
1989 
1990 
International launch of the Pharmaceutical Care 
concept in two articles entitled: “Opportunities and 
Responsibilities in  Pharmaceutical Care” 
Hepler and Strand 1989 
Hepler and Strand 1990 
1990 Definitions and categorization of DRPs (US) Strand et al. 1990 
OBRA‟90 (Omnibus Budget Reconciliation Act of 
1990), (US) 
Department of Health and 
Human Services, Health 
Care Financing 
Administration 1992 
1991 First Course in Europe on “Research Methods in 
Pharmaceutical Care” (Hillerod, Danmark) 
Herborg et al. 2001 
1992-
1995 
Minnesota Pharmaceutical Care Project (US) Tomechko et al. 1995 
1992 EuroPharm Forum was founded (Europe) http://europharmforum.org 
1993 The Tokyo Declaration (1993): FIP  Standards for 
Good Pharmacy Practice, GPP), revised versions in 
1997 and 2011 (FIP/WHO), the first global initiative  
http://www.fip.org 
1994 Creation of researchers‟ network in Europe: 
Pharmaceutical Care Network Europe (PCNE) 
http://pcne.org 
1998 Statement of Professional Standards and revised 
definition of Pharmaceutical Care, FIP Council in 
1998 (global initiative concerning FIP member 
countries) 
http://www.fip.org 
2000- National and local demonstration studies (mostly in 
USA, also in Europe, Australia and other 
continents, see Figure 2) 
Christensen and Farris 
2006, Hughes et al. 2010 
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2.1.1 The United States 
 
The philosophy of pharmaceutical care evolved from clinical pharmacy in the 
United States in the 1960s (Table 1). The first pioneers in hospital setting 
expanded the level and scope of professional functions to more patient-oriented 
services (Angaran et al. 1988). In 1975 the American Association of Colleges of 
Pharmacy (AACP) convened a board of experts in order to draw up a report 
entitled “Pharmacists for the Future”, known as the Millis Report (Millis 1975). This 
report insisted the need to involve pharmacists in the control of rational drug use. 
The Standards of Good Pharmaceutical Practice were created in 1979 in 
collaboration with the AACP and the American Pharmaceutical Association. A 
member of the working group, Dr. Brodie, described the change of the profession 
from a product-oriented to a patient-oriented practice in a conference in 1980 
(Brodie 1980). The following conferences continued the discussion, and in the 
Hilton Head Conference organized by the American Society of Hospital 
Pharmacists the term pharmaceutical care was introduced in 1985.  
 
In 1987 Hepler discussed the importance of the relationship between the patient 
and the pharmacist (Hepler 1987). In his definition the patient‟s awareness and 
commitment to the drug therapy was emphasized. Later on, Hepler and Strand 
(1989, 1990) underlined the pharmacist‟s responsibility to guide drug therapy to 
improve the quality of the patient‟s life. These publications presented the vision of 
pharmacists‟ involvement in patient care internationally in order to guide the 
development of the pharmacists‟ professional role.  
 
As the Pharmaceutical Care concept evolved in the United States, it was first 
enacted into law by the Omnibus Budget Reconciliation Act (OBRA‟90) in 1993 
which required pharmacists to counsel patients about prescriptions received 
(Department of Health and Human Services, Health Care Financing 
Administration 1992, Fulda and Wertheimer 2007). This law also implemented a 
prospective drug utilization review (pDUR) for Medicaid recipients. The law 
covered Medicaid recipients but most American states extended these services by 
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revising state laws regulating pharmacy practice to all patients receiving 
prescription drugs (Canaday 1994, Schatz et al. 2003). 
 
Minnesota Pharmaceutical Care Project was carried out between1992–1995 to 
determine whether an innovative professional practice could be implemented in 
the context of the community pharmacy emphasizing the accountability of the 
pharmacists in the patient‟s drug therapy needs (Tomecho et al. 1995, Cipolle et 
al. 1998). As a result of this project, the authors concluded that pharmaceutical 
care optimized treatments resulting in a positive outcome for patients and health 
care providers (Cipolle et al. 1998). Furthermore, the following significant findings 
were identified as a basis for professional change: 
 
1) Pharmaceutical care practice was described so it could be learned, applied 
and disseminated among other professionals. 
2) A new management system was developed to guide the profession. 
3) A payment system was designed and applied. 
4) A computerized documentation system was designed to document the 
medications of patients.  
2.1.2 Evolution internationally with special emphasis in Europe 
 
The International Pharmaceutical Federation (FIP) has been the key organization 
promoting and coordinating implementation of pharmaceutical care philosophy 
internationally. FIP has been closely cooperating with World Health Organization 
(WHO) in this respect. WHO released a document called Tokyo Declaration 1993 
on the role of pharmacists in the health care system during the FIP Congress in 
Tokyo in 1993 in order to guide the development of pharmaceutical care practice 
internationally (WHO 1993). The Tokyo Declaration was based on the FIP drafted  
document “Guidelines for Good Pharmacy Practice”  which was intended to be  a 
standard for every practicing pharmacist in order to ensure worldwide  appropriate 
quality of pharmacotherapy for every patient (Table 2) (FIP 1993). In 1997 FIP 
released jointly with WHO the “FIP statement of professional standards” in order 
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to ensure the quality of information through the relationship between the 
pharmacist and the patient to promote safe and effective use of medications (FIP 
1997). This statement was again updated in 2010 (FIP 2010) and approved by 
WHO General Assembly in May 2011. In the FIP organization Community 
Pharmacy Section has been the key coordinator of implementation of 
pharmaceutical care.  
 
Table 2 The requirements and main elements of Good Pharmacy Practice (GPP) as 
jointly defined by FIP and WHO (FIP 1993, 1997).  
The requirements of good pharmacy practice 
 
Good pharmacy practice requires that a pharmacist's first concern in all settings is the 
welfare of patients.  
 
Good pharmacy practice requires that the core of the pharmacy activity is the supply 
of medication and other health care products of assured quality, appropriate information 
and advice for the patient, and monitoring of the effects of use.  
 
Good pharmacy practice requires that an integral part of the pharmacist's contribution 
is the promotion of rational and economic prescribing and of rational use of medicines.   
 
Good Pharmacy Practice requires that the objective of each element of pharmacy 
service is relevant to the patient, is clearly defined and is effectively communicated to all 
those involved.  
 
The main elements of Good Pharmacy Practice 
 
1. Health promotion and illness-prevention 
2. Supply and use of medicines 
3. Self-care 
4. Influencing prescribing and medicine use 
 
 
In Europe, WHO EuroPharm Forum was founded in 1992 in order to involve 
community pharmacists in promoting WHO Health for All goals (EuroPharm 
Forum 2011). For this purpose, EuroPharm Forum established professional 
programs for community pharmacies in selected key areas, such as therapeutic 
outcomes monitoring in asthma, diabetes and cardiovascular diseases, 
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pharmacists‟ involvement in smoking cessation and patient counseling 
(EuroPharm Forum 2011). In order to coordinate research activities and develop 
methodology of outcomes research in this area a European platform called 
Pharmaceutical Care Network Europe (PCNE) was established in 1994 
(EuroPharm Forum 2011). Both these international organizations have been 
instrumental in implementing the new professional philosophy and related 
pharmaceutical services in European countries (van Mil et al. 2004a).   
2.2 Drug-related problems 
 
A core element of the philosophy and practice of pharmaceutical care is “to 
identify, solve and prevent drug-related problems, DRPs” (Hepler and Strand 
1990). Implementation of this process has initiated an ongoing international trend 
for developing DRP classification systems (van Mil et al. 2004b). The first 
definition of DRPs was presented by Hepler and Strand in their 1990 landmark 
article. It is as follows: “drug-related problem is an event or circumstance involving 
a patient‟s drug treatment that actually, or potentially interferes with the 
achievement of an optimal outcome” (Hepler and Strand 1990). Some years later 
in 1996, Segal published the following definition: “a circumstance of a drug 
therapy that may interfere with a desired therapeutic objective” (Segal 1996).  
 
Hepler and Strand (1990) classified DRPs into eight categories: 1) Untreated 
indications; 2) Improper drug selection; 3) Subtherapeutic dosage; 4) Failure to 
receive drugs; 5) Overdose; 6) Adverse reactions; 7) Drug interactions; and 8) 
Drug use without indication. This has inspired a vast number of other researchers 
to modify the original DRP classification by Hepler and Strand and to create their 
own definitions (e.g., Strand et al. 1990, Berardo et a. 1994, Caleo et al. 1996, 
Chen et al. 1996, Poirier and Gariepy 1996, Westerlund et al. 1999, Raynor et al. 
2000, Titley-Lake and Barber 2000, Krska et al. 2001, Gilbert et al. 2002, 
Schaefer 2002, PCNE 2002, Consensus Committee 2002). Comparisons of the 
different definitions and classifications have been presented (van Mil et al. 2004b, 
Björkman et al. 2008). The large amount of different systems indicates a lack of 
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agreement concerning both DRP definitions and classifications (Björkman et al. 
2008). The first definitions were very detailed, because of the need for research 
and documentation. Recently the definitions have been simplified and the aim is 
to apply the DRP models to the routine community pharmacy practise. These 
systems are still evolving and under lively debate in the international scientific 
literature.   
2.3 Evolution of medication management services in community 
pharmacies 
 
Even though there have been more than 20 years of development since the 
international breakthrough of pharmaceutical care philosophy, surprisingly little 
has changed in actual community pharmacy practice. The primary task of 
community pharmacists is still to dispense prescription medications and sell OTC-
medications and other health-related products. This applies to all kinds of 
community pharmacy systems worldwide. There have been attempts to provide 
cognitive services to patients and other health care professionals in different 
countries (Christensen and Farris 2006, Hughes et al. 2010, EuroPharm Forum 
2011). This chapter describes trends and achievements in community 
pharmacists‟ involvement in medication management systems by providing 
patient care services. In this review services provided by community pharmacies 
are included.  
 
Medication management means a planned system of processes and behaviours 
which determine how medicines are used by patients (Shaw et al. 2002), the 
focus being on the appropriate and safe use of medicines and on prevention of 
medication errors (NCC MERP 2005). Patient care services in community 
pharmacies related to medication management have developed in a more 
comprehensive direction (Figure 2). Disease management and risk management 
have been the earliest patient care services related to medication management 
system in community pharmacies. Disease management is a system of 
coordinated health care interventions and communications for populations with 
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conditions in which patient self-care efforts are significant (Care Continuum 
Alliance 2011). In community pharmacy settings this means routine tracking of 
key elements of a disease through health observation, record keeping, and 
regular reporting. Risk management is applied in order to promote health and 
prevent diseases. 
 
Since Hepler and Strand (1990) brought up the importance of recognition and 
documentation of drug related problems (DRPs) in assuring safe and appropriate 
medication use, community pharmacies have based their services on DRPs‟ 
recognition and documentation (Figure 2). DRPs include adverse drug reactions 
(ADRs) and drug-drug interactions (DDIs). In the United States, the first service 
concept to carry out DRP recognition has been Drug Utilization Review (DUR), 
which was described as early as 1969 in the Final Report of the US Department of 
Health Education and Welfare Task Force on Prescription Drugs (Figure 2). The 
evolution of patient care services related to medication management has led from 
distinct evaluations, such as drug-drug interaction screening, to more integrated 
and comprehensive services when all of the patient‟s medications are reviewed. 
As a result, a wide range of review services has been established, first in the US, 
and later on in other countries (Hakkarainen 2008, Figure 2). These services are 
in routine use and institutionalized in some countries (Hakkarainen 2008). Clinical 
medication reviews have been developed and adopted in Australia under the 
concept Home Medication Reviews (HMRs) (Medication Management Review 
Implementation Steering Group 2001) and in Europe in several countries (e.g., in 
UK and Finland, Hakkarainen 2008, Leikola et al. 2009, Labberton et al. 2011). In 
the United States Medication Reviews are currently included in the Medication 
Therapy Management (MTM), which also covers other health related services 
(Figure 2). According to the updated definition of pharmaceutical care (Cipolle et 
al.2004), only the most comprehensive services (MTM, clinical medication 
reviews) are implementing the philosophy and practice of pharmaceutical care, 
when pharmacists take responsibility and accountability for the drug-related needs 
of the patient (Figure 3).  
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Figure 2 Evolution of patient care services supporting community pharmacists‟ 
involvement in medication management in the United States, Europe and 
Australia. 
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Figure 3 Pharmaceutical care services implementation as a strategy in the United 
States, Europe and Australia. 
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3 HEALTH INFORMATION TECHNOLOGY IN COMMUNITY 
PHARMACIES 
Health Information Technology (HIT) is defined as a broad array of technologies 
involved in managing and sharing health information electronically (Jamal et al. 
2009). It is regarded as a tool for improving the quality, safety and efficiency of 
health systems (Chaudry et al. 2006). The HIT is expected to benefit all members 
of health care: patients, payers, physicians and pharmacies (Balfour et al. 2009) 
by improving patient care, lowering costs, increasing efficiency and productivity, 
improving communication and healthcare delivery, and improving the 
reimbursement processes (Webster and Spiro 2010).  
 
Community pharmacists started to use computer systems more than three 
decades ago (Webster and Spiro 2010). The first systems were designed for 
dispensing, billing and reimbursement purposes. Since then, applications 
have extended to a wide range of clerical and medication management 
functions. In this Chapter functions related to patient care services in 
community pharmacies  are divided into three main categories; 1) Electronic 
Health Records, including electronic prescribing and clinical decision support 
systems; 2) Health Information Technology in Medication Management; and 
3) Additional community pharmacy applications, including internet pharmacies 
and use of social media in communication on medicines. Areas of health 
information technology implementations related to patient care in community 
pharmacies are presented in Figure 4. 
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Figure 4 Areas of health information technology implementations in community 
pharmacies.  
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3.1 Electronic Health Records (EHR) 
 
There is no consensus for the definition of Electronic Health Record (EHR). 
Gunter and Terry (2005) have defined EHR as a concept for collecting longitudinal 
electronic health information about individual patients and populations, in order to 
improve quality of care. By Webster and Spiro (2010), EHR is an individual 
patient‟s medical record including patient„s demographics, medical history, drug 
history, allergies, progress notes, current medications, laboratory test results, 
radiology images and advanced directives. In the US, the Office of the National 
Coordinator for Health Information Technology (ONC) has recommended that 
EHR system should have four core functions: (1) Electronic documentation of 
providers‟ notes; (2) Results management; (3) Electronic prescribing known as 
Computerized Physician Order Entry (CPOE); and (4) Clinical decision support 
systems (CDSS) (Blumenthal et al. 2006).  
 
The EHR systems are usually managed by the national governments and with the 
consultation through international cooperation (Friedman et al. 2009). The goal of 
the future is that EHR systems will provide information transfer pathways between 
community pharmacies, physicians and hospitals. Standards are central to 
integration. Integration of community pharmacy IT systems, hospital IT systems 
and physicians‟ Electronic Medication Records (EMRs) is necessary to ensure 
patient safety and productivity benefits of using IT in health record management. 
Most of the currently used systems are implemented locally providing 
communication as one-to-one exchange messages (van der Linden et al. 2009). 
While the data sharing increases between organizations, it challenges local 
systems developed for only small-scale use. There has been recognized a need 
for larger-scale EHR system, which requires ubiquitous communication between 
systems (Figure 5) (van der Linden et al. 2009). Community pharmacies as 
dispensing medications are included in these scenarios, but their involvement in 
the system has been planned to happen in the last phases (Figure 5). The need 
has been recognized for the more comprehensive systems which allow a secure 
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clinical data sharing and support communication between health care systems 
(van der Linden et al. 2009). 
 
 
Figure 5 Sequence diagram of a HER system scenario, in which each column 
represents the respective actor in the system (PSYCH=psychiatrist, GP= 
General Practitioner, DERM=Dermatologist, LAB=Laboratory, PHARM= 
Pharmacy), „*‟ refers to implicit patient consent (van der Linden et al. 2009).  
The definition by ONC has outlined the structure of this Chapter. Since EHR is 
very broad in scope as defined, this Chapter focuses only on electronic 
prescribing and clinical decision support systems because these are the two 
functions that link pharmacies to EHR and rely on EHR data to support community 
pharmacists‟ practice. The development of these functions will establish the basis 
for the integrated EHR systems between the health care professionals, such as 
community pharmacists and physicians.  
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3.1.1 Electronic Health Records in different countries  
 
National electronic health record programs are under development and 
discussions in many countries, including Finland. These projects are challenged 
by long duration and limited resources. For this review five countries were 
selected in which 1) EHR programs have existed at least for five years; 2) the 
systems encompass various approaches of implementation; 3) pilot projects have 
been implemented; 4) published information in English or German were available 
(Deutsch et al. 2010) (Table 3). The United States (US) was added into the 
comparison in order to cover the description of health information technology 
(HIT) development in this country. The six countries included in this review were 
in different stages of their EHR implementation: Denmark and Canada have 
achieved the widest use, while Germany and Australia have implemented their 
first pilot projects (Deutsch et al. 2010). The EHR programs were analyzed on the 
basis of project reviews reported by Deutsch et al. in 2010.  
Table 3 Most advanced EHR systems (described according to Deutch et al. 2010). 
Countries are listed in alphabetical order. 
Country Name of EHR Coordinating Authority 
Australia HealthConnect National eHealth Transition 
Authority(governmentally coordinated 
organization) 
Canada Canada Health Infoway Canada Health Infoway  
(non-profit organization) 
Denmark MedCom MedCom (co-operative venture between 
authorities, organisations and private firms) 
Germany German electronic health 
card 
The gematik GmbH (owned by payers and 
providers) 
UK National Programme for 
Information Technology 
NHS Connecting for Health (governmentally 
coordinated organization) 
US Many companies 
providing EHR systems 
The Office of the National Coordinator for Health 
Information technology (ONC) (governmentally 
coordinated organization) 
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3.1.1.1 North America 
 
The Office of the National Coordinator for Health Information technology (ONC) 
was established in 2004 under the U.S. Department of Health and Human 
Services (HHS) in order to coordinate the development and implementation of HIT 
infrastructure. In 2009 Congress passed the American Recovery and 
Reinvestment Act of 2009 (ARRA 2009), which set a goal for the implementation 
of a nationwide health record system by 2014 (The White House 2009).  
 
In the US health care system there are several public and private actors and 
insurance system resulting to the fragmented EHR systems. In the US, many 
companies provide EHR systems. Even though the United States has been a 
leader in implementing new services in pharmacy practice, there has been 
criticism concerning slow adoption and use of HIT (Schoen et al. 2006, Balfour et 
al. 2009). Challenges in the adoption process have been high costs of the 
technology, general resistance to change, misaligned incentives and the fractured 
payment systems (Balfour et al. 2009).  
 
In the US, the electronic personal health record (ePHR) is an application of EHR. 
The system is initiated and controlled by the patient (Goedert 2011). ePHR can be 
generated by health care professionals, such as physicians and pharmacists, or 
by the patient. The Healthcare Information and Management Systems Society 
(HIMSS) defines ePHR as “a universally accessible, layperson comprehensible, 
lifelong tool for managing relevant health information, promoting health 
maintenance and assisting with chronic disease management via an interactive, 
common data set of electronic health information and e-health tools”. The ePHR is 
owned, managed and shared by the individual or his or her legal proxy(s) and 
must be secure to protect the privacy and confidentiality of the health information 
it contains. It is not a legal record unless so defined and is subject to various legal 
limitations (Health Information Management Systems Society 2011). Since 2001, 
patients have had right to access and even correct their own health information 
(Tsai and Starren 2001, Rashbass 2001). Ensuring privacy protection in the 
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access, storage and distribution of the patient data has been a challenge in 
the US (Mandl et al. 2001, Markwell 2001). EHR and/or ePHR have been 
seen as an opportunity for pharmacists to provide medication therapy 
management services (MTMS) by using the medical information provided by 
HER. It has been suggested that these tools could make medication errors 
nearly nonexistent in the future (Webster and Spiro 2010).  
 
In order to promote implementation of EHR in Canada, Canada Health Infoway 
was founded in 2001 (Canada Health Infoway 2006). Infoway is a not-for-profit 
organization which receives funding from the Federal Government. Infoway is 
responsible for facilitating the development, maintenance and implementation of 
the health information standards. The implementation process has been divided in 
two steps: availability (step 1) and adoption (step 2) (Canada Health Infoway 
2011). In March 2010, EHR systems were available to authorized physicians for 
22% of the Canadian population, and the target goal is to have EHR available to 
authorized physicians for all residents of Canada (Canada Health Infoway 2011).  
3.1.1.2 Europe 
 
In Europe Denmark has been one of the first countries that adopted technology in 
health care. In Denmark MedCom was founded as the national coordination 
organization for HIT to improve the efficiency and effectiveness of the Danish 
healthcare system in 1994 (Danish Centre for Health Telematics 2008). All health 
care stakeholders are part of this organization and finance MedCom. MedCom 
defines electronic data interchange formats for the health information to be shared 
through the Danish Health Data Network. In 2003, the portal was made available 
for providers and later for patients. In 2006, about 80% of the all exchanged 
healthcare information was sent electronically by the health care actors, e.g. GPs, 
hospitals and pharmacies. EU project on benefit analysis concerning the Danish 
EHR system suggested: 1) A need to define and evaluate long-term goals and 
strategies, 2) To develop precise and accepted standards, and 3) A need for 
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consensus and collaboration with stakeholders to achieve the adoption by the 
users (Wanscher et al. 2006). 
 
In the United Kingdom (UK) the National Health Service (NHS) has defined a goal 
to provide good quality health services with modern IT (NHS 2006). The EHR 
program is part of the national health care reform. The National Programme for 
Information Technology was founded in 2002, and the IT related activities were 
concentrated in the organization NHS Connecting for Health in 2005 (Deutsch et 
al. 2010). The vision of the Programme is the NHS Records Service, which will 
share a patient‟s clinical record, such as characteristics of the patient, allergies, 
adverse drug reactions and major treatments, available electronically with all 
health care providers (House of Commons Committee of Public Accounts 2007). 
The Programme includes other services, such as electronic prescription service 
(EPS), an email and directory service for NHS staff, computer accessible X-rays 
and a facility for patients to book electronically outpatient appointments. The 
Programme is expected to cost £12.4 billion over ten years, being the largest 
single IT investment in the UK to date. A status report from 2007 showed that 
80% of the planned scheduling component was implemented, 20% of the 
medication component and 30% of the national EHR system (NHS 2007). By 
2010 EHR systems‟ implementation has been delayed because of severe barriers 
challenged during the development process (Gold 2010). 
 
The German Health Reform 2003 is responsible for implementation of the eHealth 
in Germany (Bundesministerium fuer Gesundheit - Gesundheitskarte), including 
an EHR system. The target of the eHealth implementation is to improve the 
quality of the German healthcare system, its efficiency and patient empowerment. 
The project has started with the German electronic health card (Elektronische 
Gesundheitskarte; eGK) which will be the central component of the national EHR 
system in the future. In 2005, The Gematik GmbH was founded to be responsible 
for the implementation and maintenance of the eGK and the other related 
projects, such as the national EHR system (Gesellshaft fuer 
Telematikanwendungen der Gesundheitskarte mbH 2011). The organization is 
owned by health care payers and providers. In 2005, the first pilot tests in 
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implementation of German electronic health card were assessed. However, 
medical community has strongly resisted the eGK project. The main criticism has 
concerned the technical solution, poor demonstration of the added value, data 
protection, cost analysis and poor alignment of the physicians‟ requirements 
(Deutsch et al. 2010).   
3.1.1.3 Australia 
 
The Australian EHR system, HealthConnect, is based on a cooperative project 
between the Australian government and the states and territories. The goal is to 
achieve patient empowerment, quality improvements and higher efficiency of the 
health system. In 2004 the National eHealth Transition Authority (NEHTA) was 
founded to support the Ministry of Health in the implementation of EHR project, 
consisting of members of federal, state and territory governments. NEHTA is 
responsible for the coordination of the implementation, defining the relevant 
standards and terminologies, defining the patient and provider identifiers and 
supporting the legislation. The national EHR system is planned to be implemented 
by 2014. Parts of the architecture and the standards are specified and several 
regional pilots have been implemented (Deutsch et al. 2010).   
3.1.2 Electronic prescribing  
 
Electronic prescribing is electronically transmitted prescription data between 
prescribers, pharmacies, and payers. It can also include messages regarding new 
prescriptions, prescription changes or cancellation, refill requests and other 
prescription information (Webster and Spiro 2010). Electronic prescribing is 
known in European countries as ePrescribing.  In the US, the term Computerized 
Physician Order Entry (CPOE) describing the physicians‟ systems has also been 
used. The physicians create the electronic prescription in their IT system from 
where it is transmitted through a secure network and reached by the community 
pharmacy. Electronic prescribing systems have a major role in EHR systems to 
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support patient care (Figure 1). After electronic documentation, which is usually 
managed by local IT systems, electronic prescribing systems are the basis for 
integration of IT systems and sharing patient data between physicians and 
community pharmacies. The development processes of electronic prescribing 
systems have been under development since 1980s. However, only during recent 
years the systems have been implemented in routine use but are still not in wide 
spread use.  
 
The International Pharmaceutical Federation (FIP) has launched a statement of 
professional standards concerning the electronic prescribing which can be used 
when establishing national e-prescribing systems (FIP 2001). In this statement 
FIP supports the use of electronic prescribing in order to improve the quality of 
care, to reduce medication errors, to ensure security and to improve desired 
outcomes of medication therapy. However FIP indicates patient confidentiality and 
prescriber‟s intention and verification are development challenges. 
 
In Europe there has been a rapid growth in electronic prescribing adoption during 
recent years. However, there is large variation in the electronic prescribing 
systems. The technical models have varied and the models implemented earlier 
are currently obsolete. The milestones of electronic prescribing implementations 
are presented in Table 4. These countries were selected as examples because 
the technical implementation varies in their electronic prescribing systems. In 
addition to selected European countries, also the US was included (Table 4). In 
the US, RxHub is the National Patient Health Information Network™ providing 
secure access to more than 90% of people with commercial prescription coverage 
in the UnitedStates. 
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Table 4 Milestones of electronic prescribing implementations in selected European countries and the US (Medcom 2011, Gematik 
2011,Åstrand 2007, Ax and Ekedahl 2010, Surescripts 2011).  
Denmark Germany Sweden The United States 
 1995-96: MedCom I project: to 
develop and test standards for 
messaging, e.g.  prescriptions: 
communication network 
between health professionals  
 Value Added Network Service: 
electronic prescription send 
through the mailbox of the 
operator to the selected 
pharmacy 
 2009: 90% of prescriptions are 
transmitted electronically 
 2010-2011: MedCom VII 
project: e-records including 
patient information for 
professionals and patients will 
have access to  their own data 
 In the near future: Common 
Medication Card (FMK): a 
server based up-to-date card 
including patient‟s full and 
current medication  
 2005: First pilot tests of 
Elektronic Health Card (eHC ) 
(eGesundheitskarte/eGK) 
 Patient‟s PIN code essential to 
access to the shared database 
 eMedication Profile to detect 
potential risks in pharmacies 
 Expected to be in use in 
October 2011 
 1980-81: national/regional 
project formed  
 1983: the world's first 
transferred electronic 
prescription in June 
 1999: national task force formed  
 2002: new multi-disciplinary 
model for local/regional 
implementation 
 2000-2006: rapid growth of 
transferred electronic 
prescriptions  
 2005: new mandatory law 
 2005-2006: electronic 
prescription database for storing 
information  
 2009: re-regulation of the 
Swedish pharmacy market: 
- Apotekens Service AB 
takes over the electronic 
prescription database 
- all Swedish pharmacies can 
access the database 
- nearly 100% of the 
prescriptions transmitted 
electronically  
 
 2001: RxHub was created by three leading 
pharmacy benefit managers (PBMs) 
 2001: Intelligent network connection between 
physicians and pharmacies called Surescript 
founded by the National Association of Chain 
Drug Stores and the National Community 
Pharmacists Association 
 2003: the eHealth Initiave launched the 
Electronic Prescribing Project involving 
various stakeholders 
 2003: The Medicare prescription Drug, 
Improvement, and Modernization Act (MMA) 
established additional standards for electronic 
prescribing 
 2008: the Medicare Improvements for Patients 
and Providers Act of 2008 (MIPPA), provides 
incentives to physicians when they ePrescribe 
for Medicare patients 
 2008: Surescripts and RxHub merged,name 
was simplified to Surescripts in 2009 
 2009:used by 34% of office-based prescribers  
 2010: Electronic Health Record Incentive 
Program announced by the Centers for 
Medicare & Medicaid Services (CMS) for the 
Medicare and Medicaid Programs 
 2010: 91% of community pharmacies were 
connected for prescription routing 
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3.1.2.1 Electronic prescribing in Europe 
 
The world‟s first electronic prescription was sent in Sweden in 1983 (Table 4) 
(Åstrand 2007). The national monopoly (Swedish Corporation of Pharmacies, 
Apoteket AB) enabled a systematic development of an electronic prescribing 
system, which was extended in 2002 to cover all general practitioners (GPs) in the 
Stockholm‟s neighbouring area (Ax and Ekedahl 2010). The electronic 
prescription implementation strategy in Sweden was structured as a joint venture 
project between the County Council and Apoteket AB (e-Recept Stockholm). The 
electronic prescriptions are sent through by the physician to a national electronic 
prescription server (Landstingnätet, SLLnet) to the electronic prescription mailbox 
at Apoteket AB, which is used by all pharmacies (Figure 6). The patient is able to 
get the medication dispensed through any pharmacy. Each pharmacist has a 
personal PIN-code in order to extract prescriptions from the national electronic 
prescription server. The patient‟s agent can take the medicine from the pharmacy 
by having the patient‟s pharmacy card and knowing personal ID number. Today, 
nearly 100% of the prescriptions are transmitted electronically in Sweden.  
 
 
Figure 6 The technical model of the ePrescribing system in the Stockholm‟s area, 
Sweden (e-Recept Stockholm 2011).   
In Denmark, the electronic prescribing development process started in 1995–1996 
under the MedCom project, which is a co-operative venture between authorities, 
organizations and private firms, coordinating the eHealth in Denmark (MedCom 
2011). Currently, 90% of the prescriptions are transmitted electronically. The 
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Danish system is based on the communication network Health Data Network 
(SDN), which can be used by all public and private organizations for e.g., 
exchanging data, transmitting images and prescriptions. The earlier system 
developed in the 1990‟s was technologically old-fashioned because the physician 
and the patient had to decide into what pharmacy the electronic prescription was 
sent through the operator‟s mailbox. The physician receives an alert when the 
prescription has been dispensed from the pharmacy.  
 
In Germany, the electronic prescription system is based on the electronic health 
card (eGesundheitskarte/eGK) which contains a microchip (Heidelberg 2004). In 
this system the electronic prescription is saved in patient‟s health card (Figure 7). 
A PIN code for the pharmacist is needed to retrieve the prescription from the 
database. Physicians have their own professional cards to access the data, but 
the patient‟s PIN code is needed to activate the data. Also medical information 
can be saved on the card. The prescription information is on the server and can 
be opened by the PIN-code (the patient‟s or the pharmacist‟s code). The health 
card contains information that can be accessed by any provider treating the 
patient. It also can be non-server based, where the health card performs as a 
mean of transport. The weaknesses of the German system are the card costs for 
the society and the double system because both cards and the prescription 
database on the server are needed (Figure 7).  
 
 
Figure 7 The technical model of the electronic health card in Germany (modified, 
Gematik 2011).   
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3.1.2.2 Electronic prescribing and Computerized Physician Order Entry in the 
United States 
 
In the US, electronic prescribing is a process of prescribing medications using a 
computerized physician order entry (CPOE) system. Electronic CPOE systems 
exchanges prescriptions directly with the pharmacy (Virk et al. 2006). In the US, 
the CPOE systems vary in terms of functionalities included, and they have been 
available in the following graduated levels (eHealth Initiave 2004):  
 
1. Electronic drug reference, no prescribing capability 
2. Stand-alone prescription writer, with no medication history or supporting 
data 
3. Addition of basic supporting data, such like allergies and demographics, 
which can be used by the system to generate alerts 
4. Medication management – long-term tracking and monitoring of each 
patient‟s medications 
5. Connectivity among practices, pharmacies, payers and patients 
6. Integration with a more complete electronic health record  
 
In some other countries, such as Finland, only the level 5 and 6 systems are 
considered as electronic prescribing. The CPOE systems in the US have been 
quite actively studied and discussed compared to electronic prescribing systems 
in other countries.The first published studies on CPOE systems have focused on 
experiences of physicians and hospitals (Schiff and Rucker 1998, Schiff 2002, 
Shulman et al. 2005, Grossman et al. 2007). Physicians were encouraged to 
eliminate handwritten prescriptions (Institute for Safe Medical practices 2011). 
According to the studies, there have been barriers in the implementation and 
adoption of the electronic prescribing systems in the US (Grossman et al. 2007, 
Cusack 2008). The physicians who have already adopted the system have 
reported that they are costly, incentives to use are misaligned, implementations 
may be difficult and the systems often disrupt or inhibit workflow (Cusack 2008). 
Two main barriers to use the electronic prescribing among physicians have been 
reported to be: 1) The tools to view and import patient data have found to be 
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difficult to use; 2) The data has not always been perceived as useful enough 
(Grossman et al. 2011). Still both CPOE and clinical decision support systems are 
more widely adopted in inpatient settings than in outpatient one‟s. 
 
Even if there are some evidence that CPOE has reduced medication and 
transcription errors (American Society of Hospital pharmacists 1993, Bates et al. 
1998, Bates et al. 1999, Kohn  et al. 1999, Bates et al. 2001, Kuperman 2001, 
Mekhjian et al. 2002, Spencer et al. 2005, Quality Interagency Coordination Task 
Force (QuIC) to the President 2011, Institute for Safe Medical practices 2011), 
there are also several studies reporting new types of errors induced by the 
electronic prescribing technology (Bates et al. 1999, Bates et al. 2001, Ash et al. 
2004, Graber 2004, Coombes 2004, US Pharmacopeia 2005). These results may 
not be generalized to the other countries in the same extent because of the 
different health care structures, reimbursement systems and clinical practice 
(Goundrey-Smith 2006). These errors may be generated by system design flaws, 
poor decision support rules and lack of training in the functionality of systems that 
could conceivably result in errors (Coiera et al. 2006). Some of the systems have 
failed to alert clinically significant drug-drug interactions, and as a result, an 
inappropriate prescription has been generated that could potentially harm the 
patient (Bates et al. 2001). The community pharmacists‟ perspective has not been 
studied until recently (Motulsky et al. 2008, Rupp and Warholak 2008, Clauson et 
al. 2011). The variety of the systems makes it difficult to evaluate the systems and 
to make comparisons between studies.  
 
Technically electronic prescription transmission in the US community pharmacies 
utilise nodal server eRX Gateway which is a standard-based messaging engine 
between the physicians‟ electronic medical record (EMR) systems and dispensing 
pharmacies (Virk et al. 2006). The infrastructure of the CPOE system requires 
integration of patient‟s clinical data and drug history as well as pharmacotherapy 
knowledge (Schiff 2002). The capabilities include medication prescription, data 
transmission, dispensing, administration and monitoring (Virk et al. 2006). The 
system also allows processing requests for new prescriptions, modifying or 
cancelling prescriptions and refill requests.  
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3.1.3 Clinical decision support systems  
 
Clinical decision support system (CDSS) is an application that analyses data from 
the electronic health record to help healthcare providers make clinical decisions. 
The simplest models provide access to information in order to assist in decision-
making while the more sophisticated models apply patient clinical data and 
generate patient-specific treatment advice (Garg et al. 2005, Robertson et al. 
2010). Most typically systems applied in clinical practice so far have been based 
on different kinds of automated prescription medicine prompts and reminders, as 
in DUR e.g., for detecting drug-drug interactions (Becker et al. 2005).The 
community pharmacists‟ patient-focused role requires that also community 
pharmacists will have access to patient data and appropriate decision support 
systems (Calabretto et al. 2005). Medication safety is the traditional area 
pharmacists and clinical decision support systems may change prescribing 
outcomes, the effects being most consistent in the context of drug safety (Morris 
et al. 2007, Robertson et al. 2010). However, the patient outcomes produced by 
the health care software applications are rarely examined, and when studied, the 
results are inconsistent (Chrischilles et al. 2002, Garg et al. 2005).  
 
Automated prescription medicine prompts and reminders may improve patient 
care (Garg et al. 2005). Alert management for pharmacists and physicians is 
critical to achieving patient safety benefits. However, there is little literature 
describing or evaluating electronic clinical decision support systems for 
pharmacists. There is a need for ensuring a focused, limited set of evidence 
based alerts and optimizing over time based upon the data and feedback. An 
electronic prompt in variety of setting for a targeted clinical intervention has a 
significant effect on health professionals‟ behavior (Garg et al. 2005). This has 
also been demonstrated in community pharmacies (Reeve et al. 2008). 
Reminders and alerts can improve the quality, safety and effectiveness of care by 
reducing reliance on memory and presenting evidence-based clinical guidelines at 
the point-of-care (Rind et al. 1994, Evans et al. 1998, Garg et al. 2005, Saleem et 
al. 2005). However, there is also growing evidence that poorly designed, 
implemented or used clinical decision support systems may cause harm, even 
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lead to death (Bates et al. 2001). Pharmacists‟ awareness of decision support 
functionalities has recently been reported to be limited (Hines et al. 2011). In this 
interview study some pharmacists were not completely informed about the 
limitations and capabilities of their software. Pharmacists‟ knowledge and training 
would have potentially positive impact on the quality of clinical decisions (Hines et 
al. 2011). Also the IT systems used by community pharmacists have been 
reported to perform less than optimally clinically relevant interactions (Saverno et 
al. 2011).  
3.1.3.1 Computerized Drug Utilization Review in the United States 
 
In the United States (US), the first drug utilization review (DUR) programs were 
initiated in the end of 1960s (Fulda and Hass 1992). DUR is defined by the United 
States Pharmacopeia (USP) as “A process to assess the appropriateness of 
drug therapy by engaging in the evaluation of data on drug use in a given 
health care environment against predetermined criteria and standards” (USP 
1996). The aim is to prevent different kinds of drug-related problems (DRPs), 
such as drug-drug interactions (DDIs), adverse drug reactions (ADRs), as 
well as duplicate and misuse of medication. DUR became legally mandated 
by the Omnibus Budget Reconciliation Act of 1990 (OBRA‟90) in January 
1993 (Department of Health and Human Services, Health Care Financing 
Administration 1992, Fulda and Wertheimer 2007). DUR is a patient care 
service which does not represent pharmaceutical care. Alerts are performed 
at the systems level and the rules are being applied without discrimination or 
consideration for the patient as an individual. 
 
DURs are classified into three main categories: 1) Prospective DUR – evaluation 
of patient‟s drug therapy before dispensing; 2) Concurrent DUR – ongoing 
monitoring of drug therapy; and 3) Retrospective DUR – review of therapy after 
the patient has received the medication (Figure 8). The retrospective DUR (rDUR) 
was the first type of DUR implemented. It is a computer-aided program which 
reviews patients‟ medical history profiles against predetermined standards set by 
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the State DUR Board. This can happen either concurrently with the therapy or 
after it. The rDUR program is focused on the interaction between prescribing 
physician and the patient. Intervention letters, patient‟s medical profile and 
possible guidelines and publications are mailed to selected providers with 
response forms. Cost savings are calculated after the re-review conducted a year 
after the original review (Ohio Medicaid 2011).  
 
The prospective DUR (pDUR) screens patient‟s medication regimen during the 
prescription dispensing process by analysing the episodes of drug use and in 
case of potential problems alerts the pharmacist (US Pharmacopeia 1997). 
According to OBRA‟90 (Department of Health and Human Services, Health Care 
Financing Administration 1992), prospective DUR requirements have been set for 
all pharmacists dispensing medicines under Medicaid (a public health insurance 
program). After that, most state governments extended the service for all patients 
(Schatz et al. 2003). Most community pharmacists in the United States use the 
DUR software applications that are resident on their pharmacy IT systems (e.g., 
in-store computer-aided pDUR). The DUR software is also possible to use online 
(e.g., online computer-aided pDUR). Both systems generate electronic alerts 
when a prescription claim violates a pre-established criterion for appropriate use, 
which include the indication of the type of problem. Only the online system is able 
to detect the profile of all medications, not just those which are generated by one 
pharmacy which is important particular patients maintain home in more than one 
place. Concurrent DUR evaluates drug therapy and intervention, while the therapy 
is undergoing. This is targeted at patients at high risk of drug-induced illness and 
communicates the risk factors to the physicians and pharmacists involved.  
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Figure 8 Retrospective, concurrent and prospective DUR (based on Ohio Medicaid 
2011).   
In cases recognising any drug-related problems listed above (Figure 8), 
pharmacists shall try to prevent or resolve the problems, e.g., by consulting the 
prescriber. When DUR is implemented effectively, it is demonstrated to enhance 
appropriate medication use (Lyles et al. 1998, Fulda 2004).  
 
However, there have been several problems with the implementation Drug 
Utilization Review systems in the US. There has been a need for predetermined 
criteria and standards and the focus should be on significant problems based on 
scientific evidence in order to reduce the number of false positive alerts (Lyles et 
al. 1998, Chrischilles et al. 2002, Fulda et al. 2004). There is a risk that alerts will 
be overriding when they focus on insignificant problem or when the pharmacist 
receives alerts from on line systems that duplicate alerts from in store systems. 
The lack of evidence-based guidelines and recommendations are a major reason 
for the variation in the rates of intervention when preventable, clinically significant 
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problems are identified. Also there have been software application related 
problems, because of the lack of the criteria, which and how many of them should 
be included in the system (Hazlet et al. 2001). The system vendors have decided 
which criteria to be included to the system without the evidence to support the 
decisions (Chrischilles et al. 2002). An emerging critical component of the 
decision support systems is ensuring integration of alerts and making sure that 
the users are not frustrated and desensitized by encountering similar alerts from a 
variety of different systems. This “alert fatigue” is well described in the literature; 
the pharmacists desensitization is greatest when the alerts are perceived as 
repetitious, time consuming, inappropriate or not relevant to the decision; resulting 
that the users override the alerts without reading them (Lesar et al. 1997, Bates et 
al. 1999, Abookire et al. 2000, Kuperman et al. 2001, Major et al. 2002, Ahearn 
and Kerr 2003). Even when the alert system is perceived helpful, the users can 
become frustrated by being delayed by the alert, especially when they have 
difficulty interpreting the alert or receive the same alert repeatedly (Glassman et 
al. 2002, Magnus et al. 2002, Ahearn and Kerr 2003, Feldstein et al. 2004, 
Peterson and Tenni 2004). In an observational study (Chui and Rupp 2000) 
pharmacists‟ response to the alerts were observed and only 12% of the online 
alerts resulted in an intervention. There is not any research concerning critical 
evaluations of decision support systems or their outcomes (Calabretto et al. 2005) 
and only few assessing  the users‟ views and preferences concerning the 
development of alert systems (Bates et al. 2003a). 
 
The evidence of the effectiveness of DUR in preventing and resolving drug 
therapy problems has been limited (Lipton and Bird 1993, Soumerai  and Lipton 
1995), and even more systematic and standardized DUR has been suggested to 
cover all the parties and conditions (Lyles et al. 1998, Fulda et al. 2004). The US 
health system is a combination of public and private actors (Christensen and 
Farris 2006) which challenges the development of health IT with fragmented and 
several kinds of procedures. Of different DUR implementations, pDUR has been 
more difficult to implement, however all DUR implementations are needed. The 
opinions of the pharmacists have been studied to be positive towards DUR in the 
early phase of its implementation (Armstrong and Markson 1997).  
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3.1.3.2 Clinical decision support systems in Europe 
 
Within European countries, clinical decision support systems have been evaluated 
twice, in 1997 (Hartikainen 1999) and in 2010 (Landerdahl 2010). These studies 
were conducted among national organisations representing community 
pharmacies in the member states of EuroPharm Forum (Hartikainen 1999) and 
EU through the Pharmaceutical Group of the European Union (PGEU) 
(Landerdahl 2010). In 1997, ten out of 18 responding European countries reported 
having some kind of systematic clinical decision support systems (drug utilization 
review) in use (Hartikainen 1999). Four countries reported not having any 
systematic computer aided systems in this respect. These countries were Italy, 
Austria, Estonia and Finland. The most common system reported by countries 
was drug-drug interaction screening (80% of the countries) and the second most 
common was having a medical record system (60%). The most widely used 
system was in the Netherlands, where all the community pharmacies were 
encouraged to use it. In 2010, 14 EU countries reported having decision support 
systems in use (Landerdahl 2010). The most common alerts generated 
involved drug-drug interactions, duplicated medication, and contraindications. 
The most evolved systems were in the Netherlands, Germany, France, 
Portugal, Sweden and the UK. 
3.2 Health information technology in medication management 
 
Medication management is a planned system of processes and behaviors which 
determine how medicines are used by patients (Shaw et al. 2002). The focus is on 
the appropriate and safe use of medicines and on prevention of medication errors 
(NCC MERP 2005). There are many aspects related, such as avoiding potentially 
harmful drugs, drug-drug interactions and adverse reactions. Monitoring of 
medications is especially important for patients taking numbers of medications or 
patients with chronic illnesses and multiple diseases, which is common among 
elder people. Health information technology (HIT) tools are necessary in 
managing increasing volume of clinical data (Figure 1). In community pharmacies 
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cognitive services require supportive IT systems. In the following section IT 
software applications involvement in medication management functions in the 
community pharmacies are discussed.  
3.2.1 Disease management and risk assessment 
 
Care Continuum Alliance (formerly Disease Management Association of America) 
defines disease management as “a system of coordinated health care 
interventions and communications for populations with conditions in which patient 
self-care efforts are significant” (Care Continuum Alliance 2011). Disease 
management can not be considered as pharmaceutical care, because it focuses 
on a specific disease, providing patients with the tools and knowledge they need 
for taking some responsibility of their own care (McGivney et al. 2007). The 
philosophy and practice of pharmaceutical care focuses on the whole patient 
(McGivney et al. 2007). However, as a patient care service diasease management 
is often conducted by community pharmacists and requiring the support of IT. 
 
The United States (US) has been a leader in innovative community pharmacy 
services to involve pharmacies in medication management (Table 5). This also 
can be seen in the proportion of evaluated demonstration projects reported since 
1980s (Table 5). The earliest outcomes studies were conducted among patients 
with such diseases that the clinical outcomes of pharmacotherapy were easy to 
determine and measure. Examples of such outcomes are blood pressure and 
cholesterol in cardiovascular conditions, blood sugar in diabetes, and peak 
exhaling flow (PEF) in asthma. Later on, the tendency has been to apply e.g., the 
ECHO model to assess rigorously, Economic, Clinical and Humanistic Outcomes 
of the intervention of pharmaceutical service (Kozma et al. 1993). Some studies 
included patients from more than one condition groups. Not all studies include a 
comprehensive description of the service provided. This makes it difficult to 
compare different studies, but also to estimate effectiveness of a particular 
service. Furthermore, interventions can have integrated elements (e.g., education 
and monitoring), which makes it impossible to assess each element‟s impact on 
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detected outcomes. The same difficulty lies in evaluation of impact of medication 
reviews as the procedures vary a lot, e.g., in terms of comprehensiveness.  
 
In 1990s at the MacColl Institute for Healthcare the Chronic Care Model was 
launched emphasized the activation of the patients with the self-management 
support and decision support tools to ensure that the treatment decisions are 
based on guidelines (Wagner 1998, Wagner et al. 2001, Institute for Healthcare 
Improvement 2011). FIP launched a statement concerning pharmacists‟ role in 
chronic disease monitoring in 2006 (FIP 2006). It has helped to clarify definitions 
and concepts related to disease monitoring. Later on, the studies on patient care 
services in community pharmacies have also evaluated risk screening services, 
such as osteoporosis risk screening (Goode et al. 2004, Liu et al. 2007), and 
cardiovascular risk screening (John et al. 2006, Peterson et al. 2010). 
Additionally, some studies have selected participants  according to some other 
characteristics, e.g.,  patients with high risk of  drug-related problems (Malone 
et al. 2001, Taylor et al. 2003), home care patients (Meredith et al. 2002), 
patients with repeat prescriptions (Bond et al. 2000) and patients on warfarin 
therapy (Jackson et al. 2004). It is evident that more evidence on the 
outcomes of community pharmacists‟ involvement in patient care services is 
needed. Attention should be also paid on the rigorous of the research, 
particularly on study designs and outcomes measures. Of the outcomes 
measures, most challenging are related to patient‟s quality of life and cost 
optimization. Health-related quality of life (HRQOL) is an objective of 
pharmaceutical care but also a viable patient outcome (Murdaugh 1997). 
Several studies have shown that community pharmacists may improve this 
outcome by optimizing medication therapy (Niquille and Bugnon 2010). 
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Table 5 Studies on patient care services related to community pharmacists‟ involvement in disease management. 
 
Condition Study group Service Country Reference 
Several 
conditions 
Patients of all ages and conditions Detection and identification of drug-related problems (DRPs) 
(Minnesota project) 
US Tomechko et al. 1995 
 
Cardiovascular 
disease 
Patients with hypertension or heart 
failure 
Monitoring and identification of adverse drug reactions US Schneider et al. 1982 
Hypertensive patients Education and monitoring  US Park et al. 1996 
Patients with COPD Education and monitoring  US Solomon et al. 1998 
Hypertensive patients Telephone-based monitoring  US Mehos et al. 2000 
TOMCOR study in patients with 
former acute coronary episodes 
Blood pressure control  Spain Alvarez de Toledo et al. 
2001 
Patients with angina pectoris Medication review UK McGovern et al. 2001 
Hypertensive patients Blood pressure control Portugal Garcao et al. 2002 
Patients at high risk for 
cardiovascular events  
Education and monitoring (SCRIP Study*) Canada Tsuyuki et al. 1999, 2002 
Hypertensive patients Education and monitoring  Thailand Sookaneknun et al. 2004 
Dyslipidemias Patients with dyslipidemia Documentations of contributions to health and quality of life 
(ImPACT project**) 
US Bluml et al. 1998 
Patients at risk for coronary artery 
disease (patient records search) 
Pharmacist-directed lipid management program US Nola et al. 2000 
Patients at high risk for DRPs and 
with dyslipidemia 
Detection and identification of DRPs (IMPROVE***) US Ellis et al. 2000 
Patients with dyslipidemia Education and monitoring program with home visits Australia Peterson et al. 2004 
Patients with dyslipidemia Education, monitoring, detection and identification of DRPs Chile Paulos et al. 2005 
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Diabetes Asheville project 
Patients with type 2 diabetes 
Setting and monitoring treatment goals, diabetes education, 
home glucose meter training 
US Cranor et al. 2003a 
Cranor et al. 2003b 
Patients with type 2 diabetes Medication review UK Wermeille et al. 2001 
Patients with type 2 diabetes Group education Sweden Sarkadi and Rosenqvist 
2004 
Patients with type 2 diabetes and 
vascular risk factors 
Face-to-face goal-directed medication and lifestyle 
counseling, telephone-based monitoring 
Australia Clifford et al. 2005 
Patients using oral medication Management  with weekly visits or telephone calls US Odegard et al. 2005 
Patients with type 2 diabetes Management and review, education, self-management 
support and reminders 
Australia Krass et al. 2007 
Reactive 
airways disease 
Patients with hypertension or 
chronic obstructive pulmonary 
disease (COPD) 
Education and monitoring  US Solomon et al. 1998 
Patients with asthma Therapeutic Outcomes Monitoring protocol Finland Närhi 2001 
Patients with asthma Education and monitoring  Malta Cordina et al. 2001 
Patients with asthma Therapeutic Outcomes Monitoring protocol Denmark Herborg et al. 2001 
Asthma self-management tools Assisted self-monitoring South 
Africa 
Bheekie et al. 2001 
Patients with asthma or COPD Education and monitoring  US Weinberger et al. 2002 
PC in pediatric asthma Asthma management service US Stergachis et al. 2002 
Patients with asthma or COPD Peak expiratory flow rates (PEFR) measures US Weinberger et al. 2002 
Patients with asthma Telephone-based self-management advice UK Barbanel et al. 2003 
PC in pediatric asthma Asthma education and monitoring program Chile Gonzalez-Martin et al.  
2003 
Patients with asthma Rural asthma management service (RAMS) with control visits Australia Saini et al. 2008 
Pain disorders Patients with chronic pain disorders Telephon-based PC services US Gammaitoni et al. 2000 
Patients with 
musculoskeletal disorders 
Detecting and resolving DRPs using a touch screen 
technology 
US Ernst et al. 2001 
Ernst et al. 2003 
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Mental illness Patients with depression Monitoring treatment adherence and preventing relapse 
(collaborative care) 
US Boudreau et al. 2002 
Patients using antidepressants Coaching NL Brook et al. 2003 
Patients with depression Patient education, monitoring , management of adverse 
reactions and the prevention of relapse (collaborative care) 
US Capoccia et al. 2004 
Patients with new antidepressant  Telephone-based education and monitoring US Rickles et al. 2005 
Patients treated with antipsychotics Detailed monitoring and management of extrapyramidal 
symptoms  
US Stoner et al. 2000 
Other 
conditions 
Hemodialysis patients Detection and identification of drug-related problems US Manley et al. 2003 
Medicaid patients at high risk of 
DRP 
Detecting and resolving DRPs (IOWA Medicaid program) US Carter et al. 2003 
 
* Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) 
**IMPROVE study (Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers) 
*** ImPACT project (Improve Persistence and Compliance with Therapy) 
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The aim of IT supported disease management and risk assessment is to routinely 
track key elements of a disease through health observation, record keeping, and 
regular reporting in order to promote health and prevent diseases.The disease 
management systems are aimed at 1) payers; 2) health care providers, e.g. 
physicians and pharmacists; or 3) patients (Bu et al. 2007, McMahan 2008, Wyne 
2008). Payers‟ systems track and monitor information and provide feedback to 
patients and providers (Bu et al. 2007). The professionals involved in disease and 
chronic care management should increase sharing of patients‟ clinical data 
through EHR systems across care settings in a secure fashion (Marchibroda 
2008). In the US, some Medication Therapy Management programs use health IT 
to identify an at-risk population relying on patient identification, stratification of 
care, coordination of care, and safety evaluation (McMahan 2008). 
 
The disease management systems aimed at patients include educational 
resources, data-gathering systems between patient visits such as electronic diary 
tools, and/or reminders (Wyne 2008). The fourth category has been suggested 
which would integrate patient and provider technologies into a single system (Bu 
et al.  2007). IT enabled disease management can also be integrated with the 
clinical decision support systems to compare information from patients‟ electronic 
medical records against a set of rules.  
 
Diabetes has been one of the most popular conditions in disease management 
implementation (Jackson et al. 2006, Wubben and Vivian 2008). In developed 
countries, its prevalence is high, it is often associated with comorbid conditions, 
and the treatment requires multiple medications and measurement of outcomes. 
These factors provide an opportunity for the implementation of diabetes 
management systems (Wyne 2008). As an example of disease management 
software, integrated IT-enabled diabetes management (ITDM) a computer 
simulation model was created to assess the potential evidence of integrated 
system (Bu et al. 2007). This model included the registry, self-management, and 
remote monitoring technologies. The study results suggested that diabetes 
registries may be the most beneficial way to manage diabetes, while the self-
management tools alone may offer the least benefit (Bu et al. 2007). This study 
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provided evidence that ITDM improves processes of care, prevents development 
of diabetes complications, and generates cost savings. However, this model‟s 
benefits have to be weighed against implementation costs.  
3.2.2 Drug-related problems 
 
Most IT systems related to DRP screening have focused on screening drug-drug 
interactions (Becker et al. 2005). Computer-based drug-drug interactions 
screening systems are in routine use in community pharmacies in several 
countries.  
 
The first application to recognize drug-related problems with the aid of computers 
was the Minnesota Pharmaceutical Care Project 1992-1995 (Tomechko et al. 
1995). In this project the data from 5480 patients were analysed and followed for 
12 month period in community pharmacies. Of these patients, 43% presented 
DRPs and 18% had more than one DRP. 25% of DRPs occurred due to 
unnecessary or inadequate medication. Polypharmacy and several diagnosef 
were more liable to lead to these problems. Today medication management 
services are provided for the patient, health plans, practitioners and employers by 
a company called Medication Management Systems in order to rapidly implement 
medication therapy management programs with the support of IT 
(Medsmanagement 2011).  
 
In Sweden there is in a routine use a computerized application for data collection 
of detected DRPs called LRPi ATS (Drug Related Problems in ATS, the Swedish 
pharmacy computer system) and a national DRP database (SWE-DRP) for 
documenting DRPs and interventions related to non-prescription medicines 
(Westerlund et al. 1999). The program is consisted of a number of menus, from 
which usually one option was to be selected and open-ended fields to be filled out 
(Westerlund et al. 1999). This instrument was connected into an existing program 
“Symptom Advice Intervention” which includes a symptom menu and self-
medication treatment flowcharts. The pharmacists document with the help of the 
   63 
program which underlying symptom the customer was seeking help (Westerlund 
et al. 1999). Patient‟s information is not included in the documentation of these 
programs. The information of the database is used in research purposes.  
3.2.2.1 Drug-drug interaction screening 
 
Several studies have evaluated the programs for DDI screening (Jankel and 
Martin 1992, Barla et al. 1992, Hazlet et al. 2001, Barrons 2004, Perrin et al. 
2004, Becker et al. 2005, Vonbach et al. 2008, Reis and Cassiani 2010). One of 
first and most widely adapted electronic drug-drug interaction program has been 
Micromedex‟s DrugReax® developed by Thomson Micromedex 
(www.micromedex.com). Computerized screening for DDIs and other potential 
drug related problems (DRPs) are becoming available in most community 
pharmacy IT systems. This has the potential to increase the recognition of DDIs 
and DRPs beyond those detected using a manual review process (Westerlund et 
al. 2001, Chrischilles et al. 2002, Westerlund 2002).  
 
There have been several problems with the computerized DDI screening software 
in the ability to screen the clinically significant DDIs (Jankel and Martin 1992, 
Lyles et al. 1998, Fulda et al. 2000, Abarca et al. 2004). The recent performance 
of community pharmacy IT systems in screening for selected DDIs has improved 
(Abarca et al. 2006). Still the quality improvements should focus on the high 
probability of true-positive adverse clinical effects. Also quality of the database 
and how it is linked to medicinal products database can influence the proportion of 
true-positive signals.  
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3.2.2.2 Adverse drug reactions 
 
The early definition for adverse drug reactions (ADRs) was provided by WHO 
in 1970: "any response to a drug which is noxious and unintended, and which 
occurs at doses normally used in man for prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological function" (WHO 1970). Lately, 
another definition has been presented: "An appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product." (Edwards and Aronson 2000).  
 
ADRs are associated with considerable morbidity and mortality (Lazarou et al. 
1998). This latter definition emphasizes the prevention in order to avoid these 
harmful reactions. To prevent them several methods have been 
recommended including computerized prescribing (Shulman et al. 2005, 
Donyai et al. 2008), computerized screening and alerts (Bates et al. 1998, 
Chrischilles et al. 2002, Kuperman et al. 2007, Brett 2009, Roten et al. 2010), 
communication and data sharing between health professionals (Sweeney 
2002). In community pharmacy context, identification of ADRs is included in 
the computerized DUR service model in the US, and the documentation of 
ADRs is included in the LRPi ATS program in Sweden.   
3.2.3 Medication Therapy Management (MTM) 
 
Medication Therapy Management (MTM) Services were created in the US during 
2003-2004 (Bluml 2005) on the basis of philosophy of pharmaceutical care 
(McGivney et al. 2007). Numerous national professional pharmaceutical 
organizations and participants were involved in the development of the definition 
of MTM services (Bluml 2005). The process was coordinated by the American 
Pharmacists Association (APhA) in order to effectively implement and deliver the 
new MTM services to patients. The key concepts for the MTM definition were 
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outlined as follows (Bluml 2005): “1) MTM is a distinct service or group of services 
that can occur in conjunction with or independent of the provision of a drug 
product; 2) MTM encompasses a broad range of professional activities and 
responsibilities; and 3) MTM programs should include a core set of considerations 
to provide value to key stakeholders in the health care delivery system.”  
 
According to the Consensus Statement, five core elements of medication therapy 
management in community pharmacy practice were defined: 1) Medication 
Therapy Review (MTR); 2) Personal Medication Record (PMR); 3) Medication-
Related Action Plan (MAP); 4) Intervention and/or referral; and 5) Documentation 
and Follow-Up (American Pharmacists Association and the National Association 
of Chain Drug Stores Foundation 2008). All the elements included in the MTM 
model are presented in Figure 9. The services are independent, but they can 
occur in conjunction of the provision of a medicinal product. In 2003, the Federal 
Government launched the Medicare Prescription Drug, Improvement, and 
Modernization Act which for the first time on a national level included outpatient 
prescription drugs as a covered service under Medicare and allowed pharmacists 
to be reimbursed for direct patient care services (Medicare Prescription Drug, 
Improvement, and Modernization Act 2003). According to this law, the goal is that 
the service or group of services optimize therapeutic outcomes for individual 
patient. MTM services have been presented to improve patient safety by reducing 
the total number of medication-related complications (Isetts et al. 2008, Klimek 
2009, Ramalho de Oliveira et al. 2010). In this service model the pharmacists 
work in an interprofessional team and share the clinical data of the patient (Bluml 
2005). Despite the the evidence and potential opportunities of MTM services, 
there are several challenges including reimbursement, justification of the service 
and stakeholder acceptance (Pellegrino et al. 2009).  
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Figure 9 The elements included in Medication Therapy Management in the US 
(American Pharmacists Association 2011).  
MTM programs use HIT to identify an at-risk population and reach this population 
in the most appropriate measure (McMahan 2008). MTM programs that apply HIT 
use it for patient identification, stratification of care, coordination of care and 
safety evaluation (McMahan 2008). In one health care system pharmacists 
document therapeutic outcomes at every patient using a software documentation 
program (Ramalho de Oliveira et al. 2010). Barriers to MTM service delivery for 
patients have been presented to be a lack of interoperability between technology 
systems, software and system platforms (Millonig 2009), and perceived ability to 
respond to patient interest, pharmacy-related factors and enabling factors (Blake 
and Madhavan 2010).  
Medication 
Therapy 
Management 
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3.2.4 Clinical medication reviews  
 
The most advanced of the clinical medication review models developed so far 
are Medication Therapy Review (MTR) in US, Home Medicines Review 
(HMR) in Australia, and Comprehensive Medication Review (CMR) in Finland 
(Medication Management Review Implementation Steering Group 2001, 
Hakkarainen 2008, Leikola et al. 2010, American Pharmacists Association 
2011). Most of the existing medication review software are focusing on data-
storage and reporting facilities and do not provide support or reasoning 
capabilities (Healthcare Management Advisors 2003). 
  
In the US, Medication Therapy Review (MTR) is defined as one of the five core 
elements of the MTM services (American Pharmacists Association and the 
National Association of Chain Drug Stores Foundation 2008). MTR is a 
pharmacist-provided, “systematic process of collecting patient-specific 
information, assessing medication therapies to identify medication-related 
problems, developing a prioritized list of medication-related problems, and 
creating a plan to resolve them” (American Pharmacists Association and the 
National Association of Chain Drug Stores Foundation 2008). This service model 
has been shown to decrease the amounts of physician visits, emergency 
department visits, hospital days and overall healthcare costs (Bunting and Cranor 
2003, Cranor et al. 2003b, Christensen et al. 2004, Garrett and Bluml 2005).  
 
In Australia, the Home Medicines Review (HMR) service commenced operation in 
2001 (Medication Management Review Implementation Steering Group 2001). 
This service model was earlier known as Domiciliary Medication Management 
Review (DMMR) (The Pharmacy Guild of Australia 2002). In Australia, the 
medication management services are a community implementation trial of Quality 
Use of Medicines, which forms the central component of the broader medicines 
policy in Australia (Canberra 2002). The pharmacists are funded to provide 
medication management services to the patients. HMR is a patient-focused 
service, the accredited pharmacist works with the patient and the physician in 
order to evaluate medication related information with a view to identifying, 
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preventing and resolving DRPs and optimising health outcomes, especially with 
elderly. While conducting the service in interprofessional collaboration, there is a 
high potential to reduce medication errors (Chen et al. 1999, Sweeney 2002, 
Emblen and Miller 2004, Van et al. 2011). In Australia, the Pharmacy Guild (PG) 
started a project in 2001 in order to develop standards for software used in 
assisting pharmacists to conduct Home Medicines Reviews (HMRs) (The 
Pharmacy Guild of Australia 2002). Also they evaluated five currently available 
computer software applications called MiracleMMR, Mediflags, Cognicare, 
MyDMMR and Erye Care (Rigby 2004). According to these evaluations, 
Computer-based systems simplify the process of documentation and decision 
making. Some of this software contains decision support information, while others 
just enable data entry, generation of forms for remuneration and some statistical 
analysis (Rigby 2004). In Australia, there are preliminary experiences of a 
decision support system for medication review (Bindoff et al. 2007). This 
intelligent knowledge-based support system contextualizes the potential drug 
therapy problems by taking into consideration the patient‟s demographics, other 
medical conditions and drugs. The system is not based on static rules to trigger 
alerts, but utilizes a multiple classification ripple-down rules approach, which 
allows the user to build rules and knowledge base incrementally according to 
users own needs. In the pilot study of the system, the number of the rules 
progressed linearly as more cases were analyzed.  
 
In Finland, Comprehensive Medication Review (CMR) as a distinct service has a 
short history (Leikola et al. 2009). The first pilot group started medication review 
training program in 2004 and in 2009 about 100 pharmacists have been educated 
and accredited to conduct comprehensive medication reviews in Finland. CMR is 
service provided by accreditated pharmacist in a collaborative health care team 
(Leikola et al. 2009). The review should be problem-based including the 
evaluation of the patient‟s medical records, face-to-face interview, analysis, report 
and follow-up (Peura et al. 2007). The efficiency and profitability of the medication 
review service in Finland would be improved by having computer software that 
would streamline documentation, analysis and the follow-up procedures. 
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However, most challenging is the fee policy, because the service is not 
remunerated by the Finnish society. 
3.3 Internet as a facilitator of new patient care services in 
community pharmacies  
 
Patients are demanding online pharmacies, services via the internet to support 
self-care and self-management of chronic diseases increasingly in future. 
There is room for patient care innovations which potential has not been well 
utilized. Also the social media provides new opportunities because of the 
attainability, educational opportunities, and possibilities for interprofessional 
collaboration (Cain et al. 2010).  
 
The internet is one of the most successful and important technological innovation 
of our times. The users of the internet seek information about their medications 
(Berger at al. 2005, Pohjanoksa-Mäntylä et al. 2009) and share their experiences 
(Powell et al. 2003). Also pharmacies have started to provide counseling using the 
internet (Zehnder et al. 2004, Holmes et al. 2005, Ghoshal and Walji 2006, 
Pohjanoksa-Mäntylä et al. 2007, Pohjanoksa-Mäntylä et al. 2008). The internet 
has been recommended for use in communication with patients, and to enhance 
patient counseling and education (Felkey and Fox 2001). The internet technology 
offers new opportunities for pharmacists to deliver patient care services virtually 
(Pohjanoksa-Mäntylä 2010). However, the quality and reliability of the health 
information available on the internet has been a topic of concern (Impicciatore et 
al. 1997, Eysenbach and Diepgen 1998, Gottlieb 2000, Kiley 2000, Eysenbach 
2002, Eysenbach et al. 2002, Kiley 2002, Meric et al. 2002, Bernstam et al. 2005, 
Adams 2010). The internet also provides opportunities to transfer data effectively 
between health care providers. It has made possible electronic prescribing and 
sharing patient data.  
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3.3.1 Internet pharmacies 
 
Because of the demand of more individual services pharmacists have started to 
provide their services on the internet. Patients are more and more willing to use 
the internet. Internet pharmacies can provide the opportunity for consumers to 
save time and money by purchasing their medicines via internet (Weiss 2006). 
This has been typical in the United States (US), where medicines are protected by 
US patents and consumers have ordered cheaper generic drugs from Canadian 
internet pharmacies (Quon et al. 2005, Veronin 2007).  
 
A number of studies have shown a concern for patient safety (Bruckel and 
Capozzoli 2003, Montoya 2008, Bessell et al. 2002, Weiss 2006). In most cases 
the drugs purchased over internet come from other countries, the pharmacies are 
not licensed, they may provide drugs without a prescription, the drug composition 
may be something else than it should be and the patient counseling for the drug 
use is missing (Montoya and Jano 2007, Montoya 2008). Counterfeit medicines 
are estimated by WHO account for 10% of prescriptions ordered on the internet 
and the fighting against them requires international cooperation (Schweim and 
Schweim 2009). The use of internet pharmacies also provides an opportunity for 
drug misuse (Nielsen and Barrat 2009, Forman et al. 2006). Risk to patient safety 
requires regulation of internet pharmacies, through urgent national and 
international action (Ghodse 2010). In Europe, the European Court of Justice 
(ECJ) has ruled that over-the-counter medicines are allowed to be purchased 
from internet pharmacies inside EU (The European Court of Justice 2004). 
 
Unfortunately consumers are not able to recognise the danger or are easily misled 
by the online sellers, especially young consumers (Ivanitskaya et al. 2010). 
Consumers would benefit from education initiatives that develop their information 
evaluation skills and communication about the risks of buying medications online 
(Ivanitskaya et al. 2010). Despite the recognition of these risks, the use of internet 
is increasing in the pharmacy practise because pharmacists have an opportunity 
to maximize their efficiency and effectiveness.  
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3.3.2 Social media 
 
Evolution of social media is changing the way of communication in society. Social 
media has rapidly become a part of everyday life for people of all ages. There is 
great potential also for community pharmacists to use social media in providing 
patient care service such as disease and medication management (Figure 4). 
Opportunities provided by social media should be evaluated in the strategic 
planning by the pharmacy profession.   
 
Social media has been defined as a collection of Web- and mobile-based 
applications that allow individuals “to 1) construct a public or semi-public profile 
within a bounded system, 2) articulate a list of other users with whom they share a 
connection, and 3) view and traverse their list of connections and those made by 
others within the system.” (Boyd and Ellison 2008). Social media applications 
(Clauson et al. 2010, Table 6) are build on the technological foundations of Web 
2.0. that focus on connecting people by characteristics of user-generated content, 
openness and networking effects (O‟Reilly 2008). Some of these applications are 
targeted to more professional use and some are social tools. Social media can 
promote open and transparent access to health information, focused on patient 
behaviors and needs. These applications provide interactive and participatory 
environments with message-tailoring capabilities, which are different from 
traditional media such as television, radio or newspapers (Chai et al. 2009, Cain 
et al. 2010). The potential impact of social media in health care covers 1) 
Informing, educating, and empowering people regarding health issues; 2) 
Mobilizing community partnerships to recognized and solve health problems; and 
3) Researching innovative solutions to health problems (Cain et al. 2010). 
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Table 6 Overview of Web 2.0 tools and applications (Clauson et al. 2010). Originally 
published in [Pharmacists‟ duty to warn in the age of social media. Am J 
Health-Syst Pharm 2010;67:1290-1293] (c) 2010, American Society of Health-
System Pharmacists, Inc.  All rights reserved.  Reprinted with permission. 
(R1123) 
Social Media Tool Example(s) Explanation Reference 
Blogs Blogger, WordPress 
Birectional online diary that 
allows readers to post 
comments 
Boulos et al. 
2006 
RSS* aggregators 
Google Reader, 
PeRSSonalized 
Medicine, 
Pageflakes, 
Netvibes 
Software that centralizes feeds 
of customized information 
sources 
Cain and 
Fox 2009 
Social networking 
Facebook, 
MySpace, 
Linkedln, hi5, 
Ning, PharmQD 
Website that allows creation of 
personal profiles that enable 
participants to connect with 
others 
Cain 2008 
Wikis 
Wikipedia, 
MedPedia, 
AcaWiki, Knol 
Website in which anyone can 
create, modify, or delete a 
topic entry 
Clauson et 
al. 2008 
Microblogs Twitter, Yammer 
Brief form of blogging (e.g., 
140 characters) to give user 
status updates, disseminate 
information, and network with 
others 
Hawn 2009 
Podcasts iTunes 
Online digital media files that 
can be downloaded to a 
computer or personal audio 
player (e.g., iPod) 
Clauson and 
Vidal 2008 
*RSS = Really Simple Syndication 
 
 
In health care environments social media applications have shown their benefits 
in various applications. These include smoking cessation, obesity, asthma 
management, diabetes and human immunodeficiency virus prevention. Wikipedia 
(www.wikipedia.org) has become a source of health- and medicine-related 
information.  Successful outcomes from the commercial social media application 
QuitNet.com has been showed in smoking cessation among IBM employees 
(Graham et al. 2007), which suggests potential impact despite the possible bias of 
the study. During the global emergence of H1N1 virus in the US the Centers for 
Disease Control and Prevention shared an information video through a traditional 
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website receiving 100 000 hits and through a social media (YouTube) receiving 
more than 2 million hits (iHealthBeat 2011). Microsoft HealthVault and 
GoogleHealth are applications providing personal health records which give 
patients access to and control over their own health information and empowers 
them to take more responsibility of their own health. Health sites such as 
PatientsLikeMe (www.patientslikeme.com) allow networking between individuals 
with same disease to communicate, share experiences and expand their 
knowledge of their ailment.  
 
Concern has been presented that openness of social media and internet-based 
information could mislead the patient or offer inaccurate information (Ahmad et 
al. 2006). This is an important reason for pharmacists and other health care 
professionals to participate in social media as professional actors. Safety, 
privacy and professional image have been presented as risks related to online 
information sharing (Cain 2008). 
 
Pharmacy as a profession has adopted social networking slowly. However, 
community pharmacists are the most accessible health care provider to interact 
with the public (Cain et al. 2010). Social media applications provide future 
possibilities for community pharmacies to informing and educating the public and 
empower and motivate individual patients, e.g., videos for guiding admistration 
technique of asthma or other medicines could be shared through social media. 
Professional organizations and companies have assessed the suitability of social 
media for their purposes (Lukes 2010), which can be seen as an opportunity for 
pharmaceutical organizations and companies as well.  
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3.4 Future visions 
 
Community pharmacies have not fully taken advantage of the opportunities to be 
involved in patient care services to assure rational and safe medication use. 
Although the profession itself has focused on professional patient-oriented 
services various barriers have occurred resulting in slow development of these 
services with heterogeneous outcomes (Nkansah et al. 2010). In order to provide 
services, IT solutions are important tools to implement individual care plans, patient 
monitoring and sharing patient information. There are also significant opportunities 
for the use of health information technology (HIT) in the disease and medication 
management. Future research should evaluate benefits of HIT especially in the 
long-term care, establishment of methods to identify and evaluate clinical 
outcomes, and determine the cost-effectiveness of using HIT (Jackson et al. 2006).  
 
Patients‟ responsibility and involvement are likely to increase in future, fuelled by 
empowerment resulting from electronic tools for self-management. The HIT 
solutions will provide more and more sophisticated systems to manage health 
information and medication management. According to the USP (Bezolt et al. 
1993), between the years 2011–2020 pharmacists will be the most important 
source of the medical information, available 24/7 from internet applications, such 
as virtual internet pharmacies and social media (Cain et al. 2010). It is also 
possible that in the future the EHR systems will expand on an international level, 
including patient‟s medical information sharing by all the health care providers 
(Coloma et al. 2011). The increase of international collaboration is considered 
important because of the need for integration of the systems in future.  
 
Criticism has been presented towards health care system in the US: Today health 
care is characterized by more to know, more to do, more to manage, more to 
watch, and more people involved than ever before (Institute of Medicines 2001). 
These rapid changes have resulted to the chasm that the nation‟s health care 
delivery system has fallen far short in its ability to translate knowledge into 
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practice and to apply new technology safely and appropriately. A strategy for 
reinventing the system has been created with six aims for improvement: 
 
1. ”Safe: avoiding injuries to patients from the care that is intended to help 
them. 
2. Effective: providing services based on scientific knowledge to all who 
could benefit, and refraining from providing services to those not likely to 
benefit. 
3. Patient-centered: providing care that is respectful of and responsive to 
individual patient preferences, needs, and values, and ensuring that patient 
values guide all clinical decisions. 
4. Timely: reducing waits and sometimes harmful delays for both those who 
receive and those who give care. 
5. Efficient: avoiding waste, including waste of equipment, supplies, ideas, 
and energy. 
6. Equitable: providing care that does not vary in quality because of personal 
characteristics such as gender, ethnicity, geographic location, and 
socioeconomic status.” 
 
Pharmacy as a profession and as a part of health care is still in the process of 
changing with many new challenges ahead. Patients are demanding more and 
more individual services not provided at point-of-sale. These demands will impact 
community pharmacies. 
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4 IT DEVELOPMENT STRATEGIES AND PROCESSES 
 
Community pharmacy information technology (IT) systems‟ development and 
implementation require financial resources. Market areas are usually small in 
Europe because of small countries and language areas, even though there is 
variation from country to country. Resulting from the small markets, the limited 
financial resources challenge the development processes. That is why there 
should be investments in the long-term strategic planning of the IT systems in 
order to meet the needs and expectations of the users in community pharmacy 
practice. Poorly planned and implemented system slow down the work processes 
resulting their being expensive to use, and also establishing a medication safety 
risk for the patients. Important part in the strategic planning is to recognize the 
internal strengths and weaknesses of current IT systems compared with the 
needs of the community pharmacy IT systems.  
 
Patient care services provided by community pharmacies as well as the IT 
systems supporting such services can be seen as innovations. That is why their 
planning, development and implementation benefit from theoretical models which 
examine the development and implementation process. In this Chapter two widely 
used models are described which are appropriate for strategic planning and 
systematic development of innovations based on needs.  
4.1 SWOT analysis as a strategy development tool 
 
The theoretical background in the study III was a SWOT analysis which was used 
in evaluating the strategy to achieve the professional vision related to community 
pharmacy information technology supporting patient care services. SWOT 
(Strengths, Weaknesses, Opportunities, Threats) analysis developed by Albert 
Humphrey is a tool for strategic planning and for helping decision making. It has 
been used widely in the business world, but also in health care IT evaluation and 
development (Gibis et al. 2001, Casebeer 1993). The SWOT analysis is an 
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assessment of objective data subjectively organized into four quadrants: 
Strengths, Weaknesses, Opportunities and Threats (Figure 10). The model 
structures the evaluation of an entity‟s current situation with its internal strengths 
and weaknesses contrasted to its external opportunities and threats.  
 
 
Figure 10 The four quadrants of the SWOT analysis by Humphrey.   
4.2 Diffusion of Innovations as a theoretical framework 
 
The theoretical background in the study IV was the Rogers‟ described generation 
of innovations process (Rogers, 2003). Classical Roger‟s theory on Diffusion of 
Innovations has been used as a tool to guide generation of innovations in diverse 
industries since 1960‟s. In addition to guiding the actual innovation generation 
process, this theory helps to assess the readiness of a target population to adopt 
an innovation. According to Rogers (Rogers 2003), an innovation is a “new idea, 
practice or object perceived by a person or unit”, and its diffusion occurs through 
channels and within a timeframe. Rogers indicates there are four main elements 
observed in the diffusion process of innovations which are: 1) The Innovation; 2) 
Communication channels; 3) Time; and 4) The social system. Individuals achieve 
an understanding of the innovation by creating and sharing information about it 
(Rogers 2003). Initially, the diffusion of innovation model was used to understand 
agricultural innovations and their adoption. Subsequently, it has been widely and 
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productively applied in many industries, including health care (Haider and Kreps 
2004, Schommer et al. 2010).  
4.2.1 Generation of Innovations 
 
Rogers‟ Diffusion of Innovations theory guided the study IV, particularly, the 
Generation of Innovations Process (Rogers, 2003, Chapter 4). According to 
Rogers, the generation of innovations process consists of six phases. The 
process usually begins with recognizing a problem or need (Phase 1). This 
activates research and development in order to create an innovation to solve the 
problem or to meet the need (Phase 2).  Most innovations are created by scientific 
or evaluation research, which can be basic or applied research or both. The next 
phase (Phase 3) is the development phase which is often closely based on 
research putting a new idea in a form that is expected to meet the demands of 
potential adopters. Commercialization (Phase 4) converts the idea into a product or 
service, a role that is usually performed by private companies. The next important 
phase (Phase 5) consists of diffusion and adoption through communication 
channels. In the last phase (Phase 6) consequences of the innovation are observed 
and formally evaluated. These consequences can result from adoption, partial 
adoption or rejection of an innovation by individuals or social systems.  
4.2.2 Perceived innovativeness 
 
Rogers‟ taxonomy categorizes individuals and social systems according to their 
innovativeness and readiness to adopt innovations (Figure 11) (Rogers, 2003, 
Chapter 7). Innovators are the first adopters (2.5% of the population). They are 
venturesome, and able to cope with a high degree of uncertainty. Early Adopters 
(13.5% of the population) are role models for opinion leaders in their localities. 
Early Majority (34% of the population) frequently and deliberately interact, 
adopting new ideas just before the average system member. Late Majority (34% 
of the population) are sceptical and cautious, and adopts new ideas just after an 
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average system member. Laggards (16% of the population) are traditional: they 
are suspicious of innovations, and their point of reference is in the past. Rogers‟ 
theory and adopters curve (Figure 11) are based on observational data in an 
agricultural society gathered in the 1950s (Rogers 2003). This data was gathered 
by observating diffusion of farm innovations among farmers. Each adopter 
category has a different communication behavior that has been identified on the 
basis of extensive empirical research (Rogers 2003).  
 
 
 
Figure 11 Adoption categories in diffusion of innovations according to Rogers (2003).    
There has been little research concerning community pharmacists‟ willingness to 
adopt innovations. The Rogers‟ theory diffusion of innovations has been examined 
with regard to the diffusion of pharmaceutical care in the Finnish community 
pharmacies (Saario 2005) and in the implementation of patient oriented activities 
in Dutch community pharmacies (Pronk et al. 2002) to assess the process of 
adoption of patient care in daily practice in community pharmacies. Both of these 
national studies evaluated diffusion of patient care in community pharmacies by 
examining the adoption of patient-oriented services and assessing pharmacists‟ 
receptivity to these innovations. In Finland the national TIPPA-project (2000–
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2003) implemented patient care in pharmacies (TIPPA Project 2002). As a result 
of this project, a higher degree of utilizing the technology supporting patient 
counseling was reported (TIPPA Project 2005).  
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5 CONTEXT OF THE STUDY 
5.1 Finnish community pharmacy system 
 
Finland has a system of independently owned and professionally oriented 
community pharmacies that has been proactively developed by the profession 
(The Association of Finnish Pharmacies 1997, Puumalainen 2005, Ministry of 
Social Affairs and Health 2007, Ministry of Social Affairs and Health 2011). The 
community pharmacy system is highly regulated to ensure its commitment to the 
nation‟s health policy goals (Mossialos et al. 2008, Väänänen 2008, Ministry of 
Social Affairs and Health 2011). There are no chain pharmacies in Finland. In 
addition to the 600 independently owned pharmacies there are two university 
pharmacies owned by the University of Helsinki and the University of Eastern 
Finland. They have a special legal responsibility to pharmacy education and 
research (Medicines Act 395/1987).    
 
By law, community pharmacies‟ main functions are to ensure an adequate 
supply of prescription and nonprescription medicines, and their safe, appropriate 
and economical use for the general public (Medicines Act 395/1987). The 
number of pharmacies is regulated by a licensing system which is administered 
by the Finnish Medicines Agency which is part of the Ministry of Social Affairs 
and Health. The license permits the pharmacy owner who needs to be a 
pharmacist with a Master‟s degree to run the main pharmacy, and up to three 
subsidiary outlets. Pharmacy owners have both professional and financial 
responsibility for their pharmacy. The average pharmacy employs 11 staff 
members of whom about 7 have a pharmacy degree (a B.Sc. or a M.Sc. degree, 
B.Sc. pharmacists are mostly responsible for dispensing and related services, 
e.g., medication counseling). An average community pharmacy dispenses 
71,500 prescriptions per year, and the average gross revenue is approximately 
3.3 million Euros (The Association of Finnish Pharmacies 2009). The gross 
revenue is derived primarily from prescription and non-prescription medication 
sales (approximately 89% of total sales).   
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During the last decade, there have been several remarkable changes that have 
influenced economy and service provision by Finnish community pharmacies, 
some of these changes are still under way (Ministry of Social Affairs and Health 
2011). The changes that have influenced most the economy of Finnish 
pharmacies are generic substitution, implemented in 2003, and a reference price 
system, implemented in 2009 (Medicines Act 395/1987). They both have been 
effective methods for cutting drug costs paid by the society through public social 
insurance which covers the entire Finnish population. At the same time they have 
reduced pharmacy owners‟ incentives and motivation to invest in professional 
service development and provision.      
 
Because of the statement of the European Court of Justice (ECJ) has given 
permission to purchase over the counter (OTC) medicines from internet 
pharmacies (The European Court of Justice 2004), in Finland national regulations 
and instructions have been prepared to allow the internet sale of medicinal 
products (Ministry of Social Affairs and Health 2007). The law went into effect in 
2011(Law on changing Medicines Act 1112/2010), but only few Finnish 
community pharmacies have been interested in the possibility to sell OTC 
medicines from internet pharmacies. 
 
The first steps towards patient care services in Finnish community pharmacies 
were taken in the beginning of 1980s as community pharmacists‟ involvement in   
patient counseling  was mandated by law in 1983 (Medicines Act 395/1987). Five 
years later the National Agency for Medicines conducted a survey on public‟s 
expectations towards community pharmacy services in Finland. The survey 
showed most unmet needs for receipt of information about, both prescription and 
non-prescription medicines. The 1997 launch of a professional strategy for 
community pharmacy marked a milestone in the development of new roles for 
them (The Association of Finnish Pharmacies 1997). Since then, the development 
of patient care services has been more coordinated, and more strongly integrated into 
the local primary health care services (The Association of Finnish Pharmacies 1997).  
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The most  systematic effort to improve patient counseling services in Finnish 
community pharmacies was  the  TIPPA Project started in 2000 (Puumalainen 
2005, Kansanaho 2006).  According to follow-up studies using a pseudo-customer 
method in 2000-2003,   the quality and amount of counseling slightly improved 
(Puumalainen 2005). There is no evidence to show the later development in 
performance. What is known is that community pharmacists‟ importance as a 
medicines information source has increased.  In 2007, for the first time, community 
pharmacists were mentioned by consumers as a source of medicines information 
more often (87%) than physicians (82%) (Keski-Hallila 2007).  
 
Since the 1990s, the pharmacy profession, with the strong support and 
commitment of the owners‟ association (The Association of Finnish Pharmacies, 
AFP), has been actively promoting new roles and services. Three disease 
management programs; asthma, diabetes and heart disease programs, have 
been strategically prioritized because they cause major public health concern and 
the medication has a crucial role in outpatient care. The core of the pharmacy 
program is that each community pharmacy has specialized pharmacists to 
promote community pharmacies' contributions to national public health programs 
(The Association of Finnish Pharmacies 2007).  
 
Recently service development in Finnish community pharmacies has primarily 
focused on managing medications for a continuously increasing number of 
geriatric patients in primary care. This is in line with priorities of Ministry of Social 
Affairs and Health (Kivelä 2006). The pharmacy services recommended by the 
authorities (Ministry of Social Affairs and Health 2007, Ministry of Social Affairs 
and Health 2011) include comprehensive medication reviews (Leikola et al. 2009) 
and automated dose dispensing. By 2009 about 100 pharmacists were accredited 
after one and half year training to conduct comprehensive medication reviews in 
Finland. These services are quite routinely available all over the country, although their 
effectiveness and value for improving patient outcomes are still under evaluation.     
 
In the Finnish community pharmacies the current fee policy is based on dispensing 
prescriptions instead of paying for monitoring and follow-up services to assure 
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optimum therapeutic outcomes of the medications. This fee policy is a substantial 
barrier to the provision of professional services, even if there is a will in society to 
have access to those services (Kivelä 2006, Ministry of Social Affairs and Health 
2011). It seems to be extremely challenging to change the public and private pricing 
and reimbursement policies. A shift in the economic policy is possible, but 
pharmacists need to be proactive to demonstrate the added value of those changes. 
5.2 History of the IT development Finnish community pharmacies 
 
The milestones in the adoption of IT in Finnish community pharmacies are 
summarized in Table 7. The first IT systems were introduced into Finnish 
community pharmacies in the beginning of the 1980s. The first systems covered 
computer-aided dispensing, point-of-sale processing, logistics and later also 
salary calculation. In the beginning of the 1990‟s, the first features supporting 
patient care services were focused on patient information, such as leaflets and 
touch screen information systems. IT systems Linnea® and Salix® still are the 
primary IT systems used in the Finnish community pharmacies.   
 
In 2000, a health information portal called Terveysportti for physicians and 
pharmacists was launched. It included professional guidelines. Two years later, a 
pharmacy data network Apteekkiverkko was launched for community pharmacies in 
order to provide safe access to professional intranet. The first pilot of electronic 
prescribing was in 2004, and in 2007 a law requiring electronic prescribing adoption 
during the next four years was enacted. The historical development of the 
community pharmacy has been described with more details by Hynninen (2007).  
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Table 7 Milestones in adopting IT systems in Finnish community pharmacies with 
special reference to patient care services (partially based on Hynninen 2007). 
Year of 
implementation Software 
1980 The first community pharmacy IT program for processing 
prescriptions 
1986 The first computerized drug information system for prescription 
medicines (patient leaflets) 
1990 Leaflet information system of the prescription medicines for the 
patient 
1991 Self-service drug information kiosk in the pharmacy with touch 
screen 
1991 The basis programs for the current community pharmacy IT systems 
(Linnea® and Salix®) 
1997 Adopting electronic Martindale 
1997 The first drug-drug interaction-program (DrugReax®) 
1998 Electronic national pharmaceutical reference book 
2000 Health information portal for physicians and pharmacists 
2000 A checklist-type drug information database to support medication 
counseling  
2002 Pharmacy data network, national intranet for pharmacies maintained 
by AFP 
2002 Interaction programs based on SFINX-database 
2003 Demonstration program for guiding administration technique of 
asthma medicines (AFP) 
2004 Electronic prescribing (First Pilot) 
2006 Demonstration program for guiding administration technique of 
insulin (AFP) 
2007 Enact of the law concerning the electronic prescribing adoption 
during the next four years 
2008 New pharmacy IT system MAXX® launched  
2010 New pharmacy IT system pd3® launched (Pilot use)  
2011 The law allowed internet pharmacies sell otc-medicines 
2011 Program for comprehensive medication review in pilot use 
(Prodosis®) 
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5.3 Current information technology in Finnish community 
pharmacies 
5.3.1 Community pharmacy information technology systems 
 
The owner‟s association, through a national coordination group, coordinates IT 
systems‟ development for Finnish community pharmacies. The national 
coordination group consists both of owners and of pharmacists from the 
Association of Finnish Pharmacies (AFP) who have IT expertise. The coordination 
group‟s functions are to oversee and to coordinate priority IT projects for 
community pharmacies. The coordination group has access to external experts 
when needed to get a broader view of the IT issues facing community pharmacy. 
The coordination group has members from both IT system users. 
 
There are two companies in Finland developing and producing two quite parallel 
IT systems for community pharmacies. Both companies are also developing their 
new systems. The Association of Finnish Pharmacies (AFP) owns a nonprofit data 
technology company Pharmadata which develops, distributes and provides 
technical support for the Salix® IT system. It is used by 58% of all independent 
community pharmacies in Finland. Linnea® is distributed by a private company 
called Receptum. New generation of community pharmacy IT systems were 
launched in 2008, when Receptum launched an IT system called MAXX®. 
Pharmadata launched a system called pd3® in 2010 in pilot use.  
 
Both currently used IT systems Salix® and Linnea® were developed in the 1990s, 
but they have had new legally required features, e.g., the generics processing 
updates continuously. Much criticism of these IT systems has been presented 
concerning their functionalities (Teräsalmi 2006, Westerling et al. 2007, 
Westerling et al. 2010). The systems are focused on the technical processes of 
dispensing and logistics (stock management), while the support for patient care 
and cognitive services are not well supported. The system also provides the 
pharmacist a checklist of drug information to assist them with medication 
counseling. The current community pharmacy IT software does not contain 
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modules for medication management as a standard, but separate modul 
(Procuro®) is sold to cover these features, such as drug-drug interactions 
screening with classification of the clinical significance, patient‟s medical history, 
allergy notes etc. Comprehensive medication review service is still not supported 
by IT, but there is a new program in pilot use to cover this (Prodosis®). The work 
of the pharmacist has changed to more patient-focused but the IT systems do not 
fulfil the requirements of the current practice. When IT systems supporting the 
dispensing and logistics are not up to date it is more difficult for the pharmacists to 
carry out their expanded professional role.   
 
In a typical Finnish community pharmacy there are several IT workstations (Figure 
12). One-third of Finnish community pharmacies maintained a working Web site in 
2005 and 94% of those provided email medication counseling services 
(Pohjanoksa-Mäntylä et al. 2008), but the actual use of email communication has  
not  been documented. 
 
 
Figure 12 A typical Finnish community pharmacy.   
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5.3.2 Electronic prescribing 
 
In Finland the law requiring electronic prescribing adoption during the next four 
years (2007-2011) was enacted in 1.4.2007 (61/2007). This original timetable 
proved to be impossible and the postponements to the new system were 
assessed in a national distribution plan for community pharmacies. The new 
timetable required electronic prescribing adoption for community pharmacies by 
the date 1.4.2012 (61/2007, 28$), for public health care 1.4.2013 and for private 
sector 1.4.2014. Electronic prescribing will set new IT requirements in the near 
future for all health care providers. In Finland the electronic prescribing will be 
implemented as a centralized database, which is developed and maintained by 
the reimbursement office called Kela. The health care professionals will use 
personal identification cards and codes in order to access the database. The 
patient is able to choose the pharmacy and all the medical information will be 
accessed in the database with the consent of the patient. There are strict rules in 
EU governing privacy and data protection. All health care professionals will be 
required to obey the privacy and data protection requirements. 
5.3.3 Extranet applications 
 
The AFP pharmacy data network called Apteekkiverkko is used by 81% of 
community pharmacies. This network facilitates the distribution of information and 
provides the means to transmit electronic prescriptions. Since 2003, the AFP has 
maintained a national pharmacy extranet portal called Salkku first for the 
members of AFP but currently for all the community pharmacies. Its main task is 
to provide and share information for community pharmacists including 
professional information, law database and discussion forums. It also provides 
access to a national health information portal (Terveysportti), which was primarily 
designed for physicians and maintained by the Finnish Medical Society. 
Terveysportti portal contains a database of national evidence based therapeutic 
guidelines, a chronic illness database, medical news and electronic journals. 
Pharmacists also have access to this portal. However, patient records are not 
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presently shared between physicians and community pharmacies. Sfinx is a drug-
drug interaction database developed for clinical decision support systems which 
has proved to be valuable tool for prescribing and dispensing (Böttiger et al. 
2008). Other provided databases are the electronic journals database, chronic 
illness databases, e.g. kidney dysfunction or diabetes, and pregnancy and breast 
feeding databases. 
 
In Finland suppliers have own extranet portals for community pharmacies (TWD, 
Tamro; OriolaPro, Oriola). Those portals allow access to detailed information 
related to logistics and current information about the products and online 
connections. Also chain pharmacies can have their own extranets for the member 
pharmacies in order to manage marketing and logistics.  
5.3.4 Community pharmacy intranet 
 
In the Finnish community pharmacies private intranets are still rare. The first 
published information considering community pharmacy intranet appeared in 2004 
(Jansen). This early intranet application included forms, scanned information from 
the pharmaceutical companies, guidelines and regulations as well as the most 
important links to the internet. Since then, a few more pharmacies have adopted 
the use of private intranet and the contents of these sites have begun to include 
more information. Currently, the most advanced community pharmacy intranets 
also include e.g. work flow management, education material, rosters and 
compounding information. The content of the intranet could be developed further. 
Electronic forms, reports and more sophisticated tools for work flow management 
and staff communication and information are needed. An example of the contents 
of a community pharmacy intranet is illustrated in the Figure 13. 
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Figure 13 An example of a community pharmacy intranet‟s contents.   
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6 CONCLUSION OF THE LITERATURE REVIEW 
 
The pharmaceutical care is guiding the practice of the pharmacy profession 
globally. The literature review confirms that community pharmacists are 
seeking a role that encompasses both dispensing drugs and providing 
pharmaceutical services. According to this view, pharmacists believe they can 
and should do more for patient care than solely dispensing medications: they 
should also take responsibility for patient monitoring to achieve optimal 
pharmacotherapy outcomes. To do this has increased demands new 
requirements on community pharmacies‟ access to IT and the information IT 
can make accessible. However, the lack of IT solutions for cognitive service 
support limits the adoption of them. Thus, developing IT solutions is essential 
to realizing pharmacy‟s strategic goals of providing patient care and clinical 
services. The importance of IT has been noted previously although little 
research has focused on it from a strategic approach. It will be important to 
understand the community pharmacy practitioners‟ requirements for IT systems 
and to explore visions and strategic views on IT development needs in relation 
to service provided in community pharmacies.  
 
Change and IT innovations development processes might be accelerated by 
identifying internal and external strategic factors influencing it and by studying the 
theories which could contribute to making the innovation and development 
process work better. No previous study has assessed the entire process of 
innovation generation in community pharmacies. It would also be important to 
identify IT innovations that facilitate patient care services in community 
pharmacies, to evaluate their development process, and to assess community 
pharmacists‟ readiness to adopt them. The goal should be to enhance the 
community pharmacies‟ professional responsibility in the society. 
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7 AIMS OF THE STUDY 
 
The outline of the study flow is presented in the Figure 14. 
 
The specific objectives of the study were: 
1. To assess the independent Finnish community pharmacy owners‟ and the 
staff pharmacists‟ views and needs  
a. to assess independent pharmacy owners‟ views on the prioritized 
content and structure of the next generation of community pharmacy IT 
systems, and to explore which they made priorities for inclusion in the 
next Finnish community pharmacy IT system (I)  
b. to explore, whether the needs and attitudes of the pharmacy owners 
and staff pharmacists differ(II) 
c. to assess community pharmacists‟ readiness to adopt innovations (IV) 
 
2. To explore international experts‟ views and experiences with IT 
development needs and processes in relation to providing patient care 
services in community pharmacies 
a. to explore international experts‟ visions and strategic views on IT 
development needs in relation to service provision in community 
pharmacies (III)  
b.  to identify IT innovations that facilitate patient care services in 
community pharmacies (IV) 
c. to evaluate the IT innovations‟ development processes in countries with 
advanced community pharmacy systems (IV)  
d. to explore, what can we learn from other countries and development 
processes concerning pharmacy IT (IV)  
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Figure 14 Outline of the study flow.   
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8 MATERIALS AND METHODS 
 
A triangulation process was used in this study by combining quantitative and 
qualitative methods (Figure 14, Table 8). The chosen methods were a survey 
and an interview.    
 
Survey technique as a method has been widely used in pharmacy practice 
research (Smith 2002). In this study, a survey was conducted in two phases: first 
Finnish community pharmacy owners and the second community pharmacy staff 
pharmacists. A survey method was chosen which obtains knowledge from large 
number of practitioners in a short time. The survey was conducted while the 
planning process of the new information technology system for the community 
pharmacies had begun in Finland. The survey instrument included features 
related to the patient counseling, cognitive service concepts, pharmacy‟s internal 
processes as well as logistics in order to get a complete picture of the whole 
system in the community pharmacy, including the view of practitioners‟.    
 
Interviews are an example of qualitative studies which are used for gaining 
understanding of how and why people view and interpret phenomena (Smith 
2002). The researcher is able to observe and ask questions in order to gather 
deeper understanding of phenomena of interest in the context in which they occur. 
The aim of the interview conducted for this study was to explore international 
experts‟ visions and strategic views on IT development needs in relation to 
services provided in community pharmacies. Questions on the development 
process of community pharmacy IT systems in different countries were also 
included in the interviews. Subjects of interest in this area were the development 
processes in the framework of SWOT analysis and Rogers‟ Generation of 
Innovations theories. 
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Table 8 Methods used in the original publications (I-IV). 
 
STUDY 
 
METHODS 
 
 
PARTICIPANTS 
 
ANALYSIS 
I Semi-structured 
postal survey in 
2006  
All Finnish independent 
pharmacy owners (n=580), 
response rate 53% 
Quantitative analysis; 
descriptive statistics 
(frequencies, 
percentages) 
 
II Semi-structured 
postal survey in 
2006 
 
Semi-structured 
internet survey 
in 2007 
All Finnish independent 
pharmacy owners (n=580) 
response rate 53% 
 
A representative sample of 
staff pharmacists (M.Sc. and 
B.Sc.) working in Finnish 
independent community 
pharmacies (n=1709), 
response rate 22% 
 
Quantitative analysis; 
descriptive statistics 
(frequencies, 
percentages) 
III Interview study 
in 2007-2008 
A purposive sample of 
international experts (n=14) 
familiar with the philosophy 
of pharmaceutical care and 
IT development 
 
Qualitative analysis; 
Thematic content 
analysis, constant 
comparative method, 
theoretical framework 
IV Interview study 
in 2007-2008 
 
 
 
 
Semi-structured 
postal survey in 
2006 
 
Semi-structured 
internet survey 
in 2007 
A purposive sample of 
international experts (n=14) 
familiar with the philosophy 
of pharmaceutical care and 
IT development 
 
All Finnish independent 
pharmacy owners (n=580), 
response rate 53% 
 
A representative sample of 
staff pharmacists (M.Sc. and 
B.Sc.) working in Finnish 
independent community 
pharmacies (n=1709), 
response rate 22% 
Qualitative analysis; 
Thematic content 
analysis, constant 
comparative method, 
theoretical framework 
 
Quantitative analysis; 
descriptive statistics 
(frequencies, 
percentages) 
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8.1 Quantitative study (I-II) 
8.1.1 Study design 
 
The target population of the studies were the pharmacists working in the Finnish 
community pharmacies. The data of the first study were collected by using a mail 
survey that was sent to all independent pharmacy owners in Finland (n=580), in 
December 2006. Surveys were mailed by the Association of Finnish Pharmacies 
(AFP). After two electronic reminders sent through the national pharmacy intranet 
during a three week period, the study was closed. The second study was targeted 
to a representative sample of community pharmacists with Bachelor‟s (B.Sc.) and 
Master‟s (M.Sc.) degree obtained from the members of the Finnish Pharmacists‟ 
Association and the Finnish Pharmacists‟ Society. The survey study II was 
targeted at the pharmacists who were known to be employed in the community 
pharmacies. The data were collected by electronic online survey through the 
University of Helsinki. Invitation to participate in the study was send to all 2129 
community pharmacists having a registered e-mail address in January 2007. After 
one reminder by e-mail to the 1709 pharmacists, who actually had a valid e-mail 
address, the study was closed. In both survey studies the participants were asked 
to respond anonymously.  
8.1.2 Questionnaire 
 
The survey instrument (Study I and II) contained 126 structured features in two 
parts, one assessed experience with an existing IT system, and the other 
exploring features that might be included in a future IT system. This research 
report focuses the features of a future system (Appendix 1). The future IT 
system‟s list of features was derived from existing systems‟ features as well as 
potential new features, which were were identified from researchers‟ own 
professional experience and via conducting a review of the pharmacy practice 
literature concerning patient care services (Hepler and Strand 1990, WHO 2003, 
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van Mil et al. 2004a). Several additional items, such as “Online purchase of non-
prescription items” and “Hospital discharge summary”, were added to the survey 
instrument after discussion with the IT Expert Group of the AFP and pharmacy 
practice researchers. 
 
The list of features was grouped by themes into five categories: drug information 
and patient counseling (11 features); medication safety (10); inter-professional 
collaboration (10); pharmaceutical services (27) and the pharmacy‟s internal 
processes (31). Patient counseling and inter-professional collaboration were 
based on the community pharmacists‟ access to information, shared data and 
communication between health care providers. When the study was conducted in 
2006, some of the drug information and patient counseling functions were 
available in software, but they were not systematically used in Finnish community 
pharmacies. Interprofessional collaboration between the physician and pharmacist 
has been seen as a solution to reduce drug morbidity and mortality (Sweeney 
2002). Also the collaboration between different professions is needed to support 
service concepts, like comprehensive medication review (Chen et al. 1999). The 
questions about medication safety were based on classifications of drug-related 
problems (van Mil et al. 2004a, Strand et al. 1990, Schaefer 2002). These 
problems included documentation of drug-related problems, drug-drug 
interactions and adverse drug reactions. Documentation of prescribing and 
dispensing errors was also included. The list of pharmacy‟s internal processes 
was from analysis of the management processes needed in community 
pharmacies. The pharmaceutical services list was derived from professional 
guidelines and the AFP‟s pharmaceutical service visions (The Association of 
Finnish Pharmacies 1997). 
 
The perceived value of each of these features was scored using five-point Likert 
scale. The survey instrument was pilot tested for face validity and further refined 
based on the comments of ten pharmacy practitioners. The subjective 
innovativeness of the respondents was researched by the instrument of 
innovativeness (Saario 2005, based on the theory of Rogers 2003, Appendix 2). 
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These results will be reported in the Chapter 9.3 Perception of Finnish community 
pharmacy practitioner‟ innovativeness (I-II). 
8.1.3 Data collection 
 
For study I responses were received from 308 pharmacy owners (response rate = 
53%). This response rate corresponds to that typically obtained in surveys targeted to 
Finnish community pharmacists (Kansanaho et al. 2004, Kansanaho et al. 2005, 
Puumalainen et al. 2005, Teinilä et al. 2008). The gender, age and geographical 
distribution of respondents were similar to those of the target population (Table 9). 
 
For study II responses were received from 373 community pharmacists (response 
rate 22%). Of these, 34% were M.Sc. (n=128), 63% were B.Sc. (n=234) and 3% 
were students (n=11). The respondents represented 8% of the pharmaceutical 
staff members of the Finnish community pharmacies. Also in this study, the 
gender of the participants followed the gender distribution of the Finnish 
community pharmacists (Table 9). The pharmacists with the M.Sc. degree were 
more active respondents than B.Sc. pharmacists. The pharmacists aged 20-39 
were more active respondents than the older pharmacists compared to the target 
population. The pharmacists working in a large pharmacy (annual prescription 
volume over 60 000) were more active to respond to the survey than the 
pharmacists in smaller pharmacies.   
8.1.4 Analyses 
 
The data were analyzed using the Statistical Package for Social Sciences (SPSS) 
version 14.0 (Chicago, IL). Incomplete responses were included in the analysis 
and proportional data were presented in terms of the number of respondents who 
answered a particular question. Descriptive statistics were calculated and 
Pearson‟s chi-square tests were performed to examine which background 
variables were associated with pharmacy owners‟ opinions. Independent variables 
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were pharmacy owners‟ gender and age, and the size of the pharmacy in terms of 
the annual prescription volume. Large pharmacies were defined as those that 
dispense more than the average of 60,000 prescriptions per year. In the analyses, 
p<0.05 was set as the level of significance. Figures were produced by using 
Microsoft Excel® (Microsoft Corporation 2007).  
 
 1) Lääkeala numeroina 2006, http://www.laaketietokeskus.fi/tiedostot/TASKUMUISTIO040406_(ID_1102).pdf 
2) Finnish Pharmacists‟s Association 13.4.2007, Finnish Pharmacists‟ Society 21.5.2007 
3) Apteekit ja apteekkarit 2007, Tamro 
4) Association of Finnish Pharmacists 25.1.2007 (M.Sc. and B.Sc), 1.1.2007 (Owners)  
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Table 9 Characteristics of the respondents (staff pharmacists, n=373; pharmacy owners, n=308) and the study populations (staff 
pharmacists, n=4498; pharmacy owners, n=580) (n.a. means “not available”). 
  Pharmacy owners Staff pharmacists (M.Sc. and B.Sc.) 
 Respondents Target population Respondents Target population 
  % n % n % n % n 
 
Degree 
              1)   
B.Sc. (Pharm.)     65 234 81 3674   
M.Sc. (Pharm.)     35 128 19 824   
Gender    4)    2)   
Female 70 199 70 420 91 338 93 3426   
Male 30 87 30 184 9 35 7 255   
Age (years)           
20-29 0 0 0 0 28 105 n.a. n.a.   
30-39 0 0 0 0 40 149 n.a. n.a.   
40-49 18 56 18 108 21 78 n.a. n.a.   
50-59 48 146 47 281 9 34 n.a. n.a.   
60 years and over 33 101 36 215 2 7 n.a. n.a.   
Annual prescription volume    3)    4)   
< 40 000 31 96 51 387 21 77 9 395   
40 000 – 80 000 46 140 30 231 28 104 36 1520   
> 80 000 23 69 19 148 51 192 55 2372   
Geographic location of pharmacy (provinces)    4)    4)   
Southern Finland 37 111 34 207 44 161 42 1880   
Eastern Finland 16 48 13 81 15 54 12 523   
Western Finland 34 103 39 239 32 119 35 1534   
Oulu 10 31 9 54 7 25 8 375   
Lapland 4 11 4 22 3 10 3 138   
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8.2 Qualitative study (III-IV) 
8.2.1 Study design 
 
Qualitative semi-structured theme interviews were conducted with a purposive 
sample of international experts to explore the visions of the participants in relation 
to community pharmacy services and implementation of IT to support service 
providing. This method was selected because it allowed the interviewer to re-
word, re-order and clarify each question based on the responses of the 
participants (Tong et al. 2007). The study was designed in accordance with the 
RATS guidelines for conducting and reviewing qualitative research (Clark 2003).  
 
The first part of the interview was designed to facilitate a SWOT (strengths, 
weaknesses, opportunities, threats) analysis discussed in more detailed way in 
Chapter 4.1. The second part of the interview was designed to identify IT 
innovations in community pharmacies and to examine their development process 
from an international perspective. Rogers‟ Diffusion of Innovations theory guided 
the research, particularly features concerning the Generation of Innovations 
(Rogers, 2003). This theory has been discussed in Chapter 4.2. 
8.2.2 Study participants 
 
A purposive sampling strategy was employed to seek perspectives from a broad 
range of participants with special expertise. The inclusion criteria were that the 
experts: 1) were familiar with pharmaceutical care as a philosophy and its 
implementation in community pharmacies, and 2) have been involved in the 
development of community pharmacy IT systems. The participants were selected 
from eight developed countries with advanced community pharmacy IT systems 
(Table 10). The final sample size was determined by the point when data 
saturation occurred (when no new categories, themes or explanations emerged). 
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Potential participants were informed about the study and invited to participate by e-
mail. All participants provided written informed consent to participate in the study.  
 
Table 10 Study participants (n=14). 
Employment status n 
 University professor 3 
 Researcher 2 
 Pharmacy owner 3 
 Manager in a national association 2 
 IT expert in a national association 2 
 Manager in a private company  1 
 Government policy analyst specialized in medication 
management 
1 
Country  
 Australia 2 
 Finland 4 
 The Netherlands 2 
 Portugal 1 
 Sweden 1 
 Switzerland 1 
 The United Kingdom 1 
 The United States 2 
Gender  
 Females 7 
 Males 7 
Language   
 Native English 5 
 Other language 9 
8.2.3 Interview guide and data collection 
 
The interviews were conducted with the aid of a semi-structured interview guide 
(Appendix 3).  The interview guide was used to stimulate open discussion on pre-
determined themes (Smith 2002), which related to the experts‟ visions for 
community pharmacy services and IT development. The interview guide was pre-
tested for face-validity by conducting one pilot interview. No modifications were 
deemed necessary. Data from the pilot interview were not included in the final 
analyses. Although the informants were strategically selected, most of the 
  
 
 
 
103 
interviews (n=9) took place at the World Congress of Pharmacy and 
Pharmaceutical Sciences in 2007-2008, because it was a convenient way to meet 
the selected experts in person for an interview. Interviews with Finnish experts 
were conducted in Finland in 2007-2008. One of the international experts was 
interviewed by e-mail. The interviews lasted between 22 to 73 minutes each. All 
the interviews were conducted in English except for the interviews with the Finnish 
participants, which were conducted in Finnish.  
8.2.4 Analyses and coding framework 
  
With the written consent of the participants, all the interviews were digitally audio-
taped and transcribed verbatim. Interviews with the Finnish participants were 
translated into English. Each transcript was repeatedly read by a researcher while 
listening to the audiotapes. A constant comparison approach was used to identify 
emerging patterns and key themes (Boeije 2002, Silverman 2000). Single words, 
sentences or groups of sentences related to a particular theme were coded by 
one researcher and verified by another researcher.  
 
The themes from the data were subjectively organized into following areas: 
visions about patient care services; visions on IT; concerns on patient care 
services; and concerns on IT. By using SWOT analysis the themes from the 
data were subjectively organized into four quadrants: internal strengths and 
weaknesses, external opportunities and threats. Sub-themes that emerged 
under these quadrants were also coded. The data from the second part of the 
interview were subjectively organized based on the Rogers‟ (2003) theoretical 
framework of the Generation of Innovations Process into the six phases 
(Problem or Need; Research; Development; Commercialization; Diffusion and 
Adoption; Consequences). Any differences of interpretation were resolved 
through discussion with the other researchers in the group. Once key themes 
were identified the transcripts were purposively re-read to detect any 
discussion that deviated from these themes. When interpreting the data the 
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researchers remained aware of any potential biases, including their 
professional backgrounds (all were pharmacists).  
8.2.3 STUDY III Visions for community pharmacy IT systems and patient care 
 
The first part of the interview was designed to explore visions concerning  patient 
care and applying IT to support providing cognitive services in the community 
pharmacy practice and strategic views by facilitating a SWOT (strengths, 
weaknesses, opportunities, threats) analysis (Appendix 3, Part I). The experts‟ 
interviewed were asked to identify future patient care and community pharmacy 
service needs, as well as the future of the development of community pharmacy 
IT systems. The question order was planned so that the future vision related 
questions were asked first and the questions related to the current situation were 
asked after that. The reason for this sequence is that the experts were asked to 
give their assessments without priming due to thinking about current systems‟ 
capabilities. The survey respondents were asked to identify opportunities and 
threats for their vision of the future to be realized. They were also queried about 
the strengths and weaknesses of the current IT systems.  
8.2.4 STUDY IV Generation of innovations in community pharmacy IT  
 
The second part of the interview was focused on the generation of innovations in 
community pharmacy IT. The semi-structured interview guide was derived from 
Rogers‟ theory (Rogers, 2003) including topic headings and open-ended 
questions (Appendix 3, Part II). The interview guide was used to stimulate open 
discussion on pre-determined themes (Smith 2002), which related to the experts‟ 
opinions on IT innovations and their diffusion process into the community 
pharmacy practise. First, the respondents were asked to name the key 
innovations in their countries‟ community pharmacy IT systems specifically related 
to medication management and patient care services. Following the 
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Generation of Innovations Process, they were asked to discuss the phases of 
the process with regard to particular IT innovations they identified. Finally, the 
experts were asked about their recommendations for national community 
pharmacy IT development processes.  
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9 RESULTS 
9.1 Priorities for IT system among Finnish community pharmacy 
owners (I) 
 
A total of 308 responses were received from Finnish community pharmacy owners 
(response rate 53%). The gender, age and geographical distribution of 
respondents were similar to those of the target population (Table 9). According to 
the respondents, features related to stock management, patient counseling and 
facilitating cognitive pharmaceutical services were prioritized for inclusion in a new 
IT system (Figure 15). Of these functionalities, tracking product expiration (100% 
of respondents regarded it as very or quite important) and drug-drug interaction 
(DDI) tracking software programs (99%) were rated highest, followed by the online 
national reference book (97%) and drug information database to support patient 
counseling (95%). Of the new IT services that were in a pilot testing at the time of 
the survey, the brief medication review and the comprehensive medication review 
(CMR) were considered very or quite important by 91% and 84% of the 
respondents, respectively. Establishing an online connectivity between the 
community pharmacy and partner providers (e.g., physicians and insurance 
companies) and supporting electronic prescribing were perceived as important. 
The lowest priorities were for features related to monitoring the laboratory test 
results (18% regarded it as very or quite important); checking patients‟ medication 
cabinets (22%); and medication monitoring and vaccination services (25%). 
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Figure 15 The top 30 features prioritized by the pharmacy owners. 
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74 % 
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75 % 
79 % 
90 % 
88 % 
0 % 10 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 100 % 
Ability to generate electronic invoices (n=305) 
Documenting of adverse drug reactions (n=307) 
Automated dose dispensing (n=303) 
Reporting system for substandard products (n=306) 
Accounting (n=304) 
National current care guidelines (n=302) 
Documentation of drug related problems (n=306) 
Alert system for supply problems (n=303) 
Documentation of dispensing errors (n=308) 
Logbook for continuing professional development (n=305) 
Online repeat of prescriptions (n=307) 
Documentation of drug-drug interactions (n=307) 
Pharmacy protocol for medication counseling (n=307) 
Guidelines for drug administration technique (n=308) 
Analysis of stock moving speed (n=302) 
Comprehensive medication review (n=304) 
Electronic information from the pharmaceutical companies 
(n=306) 
Self-medication guidelines (n=304) 
Tool for staff communication (n=305) 
Link to a health portal (n=305) 
Updated product information for pharmacists (n=303) 
Brief medication review (n=302) 
Electronic prescribing (n=304) 
Online reimbursement service (n=307) 
Ability to generate orders based on sales (n=304) 
Managing stock holding (n=303) 
A checklist-type drug information database to support medication 
counseling (n=306) 
Online national reference book (n=308) 
Drug-drug interaction program (n=302) 
Tracking product expiry (n=305) 
Very important Important No opinion To some extend important Not important at all 
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The respondents‟ gender was the variable most commonly associated with 
respondents‟ priorities for new IT system. Female pharmacy owners gave a higher 
priority to drug information and patient counseling, pharmaceutical services and 
the pharmacy‟s internal processes than did their male colleagues. The influence 
of the respondent‟s age was seen in the preference ratings for drug information 
and patient counseling, inter-professional collaboration and pharmaceutical 
services. There was a tendency for those aged 50-59 years to prefer these 
functions and to see them as more important than did either younger or older 
owners. The size of the pharmacy had a minor association with respondents‟ 
priorities. Owners of large pharmacies (over 60,000 prescriptions per year) 
identified some items with regard to drug information, patient counseling 
categories, and from internal processes of the pharmacy as being more important 
than did the owners of the small pharmacies. Medication safety was an area of 
agreement were respondents had similar, high opinions on the importance of 
these IT tools regardless of their gender, age and size of the pharmacy.  
9.2 Opinion comparison concerning IT system in Finnish 
community pharmacies (II) 
 
A total of 308 responses were received from the pharmacy owners (response rate 
53%) and 373 responses from the staff pharmacists (response rate 22%). Of 
these, 34% had a M.Sc. degree (n=128), 63% had a B.Sc. degree (n=234) and 
3% were pharmacy students (n=11).  The staff pharmacists with the M.Sc. degree 
were more active responders than B.Sc. pharmacists (Table 9). Also the owners 
and pharmacists working in large pharmacies were more active responders.  
 
More than half (52%) of the potential features for future IT system listed in the 
survey questionnaire (Tables 11 and 12) resulted in different responses from the 
community pharmacy managers and staff pharmacists. The features related to the 
pharmacy‟s internal processes, such as financial management, sales and 
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marketing management and stock, were ranked significantly higher by the owners 
and managers, while the personnel prioritized the features supporting 
pharmaceutical service provision and personnel management. Managers and 
personnel had similar opinions on the importance of features supporting drug 
information, patient counseling, medication safety and interprofessional 
collaboration. Owners and managers gave the highest ranking for features related 
to stock control (tracking product expiration, ability to generate orders based on 
sales, and managing stock holding), electronic prescribing and online 
reimbursement service (Table 11). Correspondingly, the staff pharmacists working 
in customer service ranked online access to national reference book, 
documentation of medication misuse, disease management for asthma and 
program to support work orientation the highest (Table 12). 
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Table 11 The features prioritized significantly higher by the managers (owners, n=234 
and M.Sc., n=128) for the community pharmacy IT system in Finland (p-
values of Likert scale, Chi square test). The percentual results are presented 
as a combination of Very important and Quite important responses. 
            Managers B.Sc. 
            %   % p 
Drug information and patient counselling (none of 11 items) 
Medication safety (1 of 10 items) 
Reporting the substandard products to the wholesaler 77 61 <0.001  
Interprofessional collaboration (2 of 10 items)                                                                   
Online reimbursement service      92 81 <0.001 
Online contacts with the insurance companies   63 49 0.002 
Pharmaceutical services (8 of 27 items) 
ePrescribing          92 85 <0.001 
Methadone program        34 30 0.001 
Automated dose dispensing         72 50 <0.001 
Online drug order from customer to the pharmacy     50 38 <0.001 
Patient‟s medication cost report        55 46 <0.001 
Product reorder alert based on customer      69 56 0.002 
Remindments of medication by e-mail or text message  48 35 0.004 
Online purchase of non-prescription items    29 9 <0.001 
Pharmacy’s internal processes (20 of 31 items) 
Financial management (7 of 7 items) 
Accounting            76 30 <0.001 
Budgeting            63 24 <0.001 
Salary calculations          72 38 <0.001 
Credit control           56 23 <0.001 
Short-time financial planning        47 17 <0.001 
Ability to generate electronic invoices       77 30 <0.001 
Financial forecasts            55 20 <0.001 
Personnel (none of 10 items) 
Sales and marketing management (8 of 8 items) 
Space management          68 63 <0.001 
Marketing            70 65 <0.001 
Calendar for campaigns         74 61 <0.001 
Planning the assortment         77 68 <0.001 
Customer analyses          69 47 <0.001 
Complaints handling          74 59 <0.001 
Electronic cold facilities monitoring        69 61 <0.001 
Electronic forms for pharmacy        76 63 <0.001 
Stock (5 of 6 items) 
Ability to generate orders based on sales      94 84 <0.001 
Tracking product expiry       100 93 <0.001 
Managing stock holding         94 87 <0.001 
Following the delivery assurance of other companies     78 67 <0.001 
Analysis of stock moving speed            80 64 <0.001 
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Table 12 The features prioritized significantly higher by the staff pharmacists (n=234) 
than by the managers for the community pharmacy IT system (p-values of 
Likert scale, Chi square test).  The percentual results are presented as a 
combination of Very important and Quite important responses. 
            B.Sc. Managers 
            % % p 
Drug information and patient counselling (1 of 11 items) 
Online national reference book      97 96 <0.001 
Medication safety (1 of 10 items) 
Documentation of medication misuse     80 73 0.004 
Interprofessional collaboration (1 of 10 items) 
Online network between disease management pharmacists 69 60 0.001 
Pharmaceutical services (5 of 27 items) 
Medication compounding program     62 51 <0.001 
Pricing program for extemporaneous products   75 71 <0.001 
Disease management program for asthma    80 74 0.044 
Peak Flow measurement (documentation for follow-up)  47 47 0.012 
Smoking cessation program       65 56 0.003 
Pharmacy's internal processes (7 of 31 items) 
Financial management (none of 7 items) 
Personnel (7 of 10 items) 
Staff roster          79 74 0.006 
Staff workflow         55 51 0.004 
Vacation roster         73 65 0.002 
Managing staff expertise of personnel     66 58 0.001 
Recruitment          48 39 <0.001 
Orientation          80 74 0.001 
Termination of an employment      45 44 <0.001 
Sales and marketing management (none of 8 items) 
Stock (none of 6 items) 
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9.3 Perception of Finnish community pharmacy practitioners’ 
innovativeness (I-II) 
 
The results of the subjective innovativeness of the survey respondents were 
compared to the earlier studies conducted by Pronk in the Netherlands in 2002, 
Saario in Finland 2005 and Rogers in the US (Figure 16). The shapes of the 
diffusion curves generally followed the bell distribution reported by Rogers in 
2003. However, the pharmacists‟ curves were skewed more towards the innovator 
than laggard categories, which deviated from Rogers‟ generic model (Rogers 
2003). One interviewee described pharmacy and innovations as follows: 
 
“On the field of pharmacy there has not been very strong tradition for the 
generation of innovations, at least in Finland, hardly anywhere. Maybe lately there 
have been some trends that people have set up firms to do something brand new, 
but there have not been strong traditions for that.“ 
 
Figure 16 Self-reported innovativeness of Finnish and Dutch pharmacists compared to 
Rogers‟ innovativeness curve (Pronk et al.2002, Rogers 2003, Saario 2005).    
  
 
 
 
113 
9.4 Visions of the pharmaceutical care and the IT systems for the 
community pharmacies (III) 
9.4.1 Visions on Community Pharmacy Services and IT Support 
 
The majority of the interviewees strongly supported the patient care service 
orientation of community pharmacy (Table 13). Their vision was that 
pharmaceutical care services will be recognized and that reimbursement will be 
provided to pharmacists providing services. This development was seen as a 
logical extension of the community pharmacists‟ professional role in health care. 
The interviewees emphasized that pharmacists should concentrate on what their 
professional education prepared them to do. Visions related to IT included 
optimization of the work, IT-based documentation and follow-up of the medical 
therapy, shared patient data, access to evidence-based information and 
guidelines, and technological solutions, such as electronic prescribing. The 
interviewees agreed that the presence of IT is an essential tool for community 
pharmacists‟ pharmaceutical care services provision.   
 
The experts also expressed concerns about or raised issues related to 
pharmacists‟ involvement in patient care (Table 14). These issues related to 
increasing commercialism, differentiation of pharmacies, the public image of 
pharmacies, and political decisions. Experts were concerned that IT will be solely 
used for accelerating the dispensing process rather than facilitating greater 
allocation of resources to provision of patient care service.    
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Table 13 Future visions on patient care services and information technology in 
community pharmacies. 
Visions on patient care services 
Acting as a part of the 
health care 
“They (pharmacies) should be point of health care for patients.” 
(professor) 
Emphasis more in 
service provision  
”…Pharmacies will start not only dispensing medication but 
also delivering services. I hope that they start being payed and 
recognized for these services.”(manager) 
Consultative role  “...When we think the educational background, the role will 
probably be more consultative than these days. Today we are 
concentrated on selling products.” (IT-expert) 
Treatment follow-up 
services 
“If today we are talking more about diabetes, hypertension, 
ashtma, maybe in five years we will have much more health 
related issues...” (manager) 
Collaboration with 
physicians 
“I hope the relationship between the physicians and 
pharmacies will get closer. They are just trying to take the first 
steps now.” (manager) 
Individual patient focus “Trying to help the patient with your knowledge takes more 
time than just selling drugs, but I think the patient is looking for 
this. He doesn‟t want to be one patient among a lot of patients, 
when you are in face-to-face situation, he is THE 
patient.”(owner) 
Professional 
specialization and 
outsourcing 
“The pharmacists will be more specialized.” (IT-expert) 
Visions on information technology 
Optimization of the 
work 
“Stop doing so much the technical work like labelling and all of 
that and to do for technicians or machines.” (researcher) 
IT-based 
documentation and 
follow-up  
“Two of the important cornerstones in pharmaceutical care are 
documentation and follow up. And it is very hard to make the 
follow ups in patients‟ visits if you don‟t have any IT-based 
documentation. So I think these are necessary tools to be able 
to conduct pharmaceutical care in its original meaning.” 
(researcher) 
Shared patient data 
 
“The professional organizations, the doctors, the pharmacists 
but also the patient groups should have shared vision in order 
to share the patient data, because of patient safety.” 
(researcher) 
Access to evidence-
based information and 
guidelines 
“If we think the consultative role, the idea in this is the critical 
evaluation and combining of the information, which is from 
different sources and that is exactly the area where we are 
good at. In order to work there has to be an information 
technology system supporting that.”(IT-expert) 
New technology 
solutions available 
“ I think in ten years we will have ePrescribing and we will have 
a system for access in the patient data from any pharmacy.” 
(researcher) 
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Table 14 Future concerns on patient care services and information technology in 
community pharmacies. 
Concerns on patient care services 
Business interest “Many individual owners of wider pharmacies focus on their 
businesses and are not interested in the future of the 
profession.” (researcher) 
Differentiation of 
pharmacies 
“There is a worldwide movement for community pharmacies to 
differentiate themselves. So what we will see is some 
pharmacies moving more to health while we see other 
pharmacies moving more to look like supermarkets etc.” 
(professor) 
Public image “…The image that pharmacy put to the public is also a place 
where you can buy all sort of commercial items; hair dye, 
shampoo, everything, nappies, and not so much a place for 
health and a place where you get health services.” 
(researcher) 
Insufficient patient 
outcomes 
“They (pharmacists) did not yet take their responsibilities 
seriously enough in order to be responsible for patient 
outcomes. (professor) 
Competition with other 
health care providers 
“...We have a competition with other health care providers, 
nurses are doing case managements, positions they don‟t want 
to let go, diagnosis, prescribing, it is that rational and 
political...”(professor) 
Political decisions “As a profession we have got in some way limited opportunities 
to affect the things, which will happen.” (owner) 
Sustainable economics “…If they (pharmacists) want to keep the profits moderate, they 
have think what is the central issue and concentrate on that.” 
(IT-expert) 
Concerns on information technology 
Effectiveness “...You have to use the time you have won by good IT-solutions 
to develop more time for the patients instead of maybe serving 
more patients per hour.” (researcher) 
Data protection “IT actually is providing information about new competition 
interaction check or to patient‟s complex history of drugs or the 
shared file. You need for this a very secured way because of 
the data protection.”(owner) 
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9.4.2 Opportunities and threats to achieve the vision 
 
IT was identified as providing an opportunity to help achieve the vision to provide 
patient care services (Table 15). Professional skills were considered essential to 
better use of IT and clinical knowledge in provision of services. The new 
generation of pharmacists was described as having improved skills and attitude in 
relation to patient care and the use of IT.  
 
Nine different threats to utilizing IT to support for patient care were described; the 
most common was the cost associated with developing new IT applications that 
could be incurred by independent pharmacy owners or governments. Another 
threat raised was that IT applications are not available to meet the needs of 
community pharmacists‟. Community pharmacists not having a patient-oriented 
attitude was also cited as a threat. Collaboration with other health care providers, 
privacy protection and time constraints were also mentioned.  
9.4.3. Strengths and weaknesses of the current IT systems 
 
Some of the experts regarded the reliability of the current IT systems to be strength. 
The current IT systems were perceived as facilitating low cost standard dispensing 
of prescriptions. A strength mentioned by one expert was that the need for change 
has been recognized by the profession. Another strength was that technological 
capability exists to manage patient care, even if these features are not widely used 
in pharmacy practice. The most often mentioned weakness was that IT is presently 
focused on dispensing rather than on supporting patient care. Underuse of the 
current systems was described as partially resulting from a lack of IT skills.  
  
  
 
 
 
117 
Table 15 Internal and external factors related to patient care services and IT support in 
community pharmacies (SWOT analysis of expert opinions, n=14). 
 
Strengths 
 
Current IT systems are useful (n=2) 
Cost effectiveness (n=1) 
The need for change is recognised (n=1) 
Reliability (n=1)  
Technological capability exists, even if it 
is not used much (n=1) 
The system is very sophisticated (n=1) 
 
 
Weaknesses 
 
 IT is focused on the dispensing process 
rather than supporting patient care 
services (n=6) 
Pharmacists‟ attitude against change 
(n=4) 
Underuse of the current systems (n=2) 
The poor quality of the systems (n=1) 
The lack of patient safety (n=1) 
The lack of vision (n=1) 
The lack of competition between the 
system vendors (n=1) 
The systems are out of time (n=1) 
 
 
Opportunities and facilitators 
 
IT solutions (n=10)  
Professional skills (n=5)  
New generation of the pharmacists (n=3)  
Interprofessional collaboration (n=2)  
Patient oriented attitude (n=2)  
The fee policy (n=1) 
The evidence of patient outcome (n=1) 
The consistency of the profession (n=1) 
The management change (n=1) 
 
 
Threats and barriers 
 
Costs (n=9) 
Attitude (n=4) 
The IT solutions are not available (n=4) 
Competition with other health care 
providers (n=3)  
The behavioural changing process (n=2) 
Privacy protection against information 
sharing (n=2) 
Lack of integration of professional 
services with the economics and 
pharmacy (n=1) 
Time constrains (n=1) 
Quality of information shared through 
internet by industry (n=1) 
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9.5 The processes for generating community pharmacy practice 
IT innovations (IV) 
 
The interviewed experts collectively named 14 different key IT innovations which 
can be classified in three main categories (Figure 17). Each respondent named 0-
5 different innovations, of which electronic prescribing and other IT systems 
supporting electronic health data management were most often mentioned. Some 
interviewees had difficulty in naming specific IT innovations. 
 
“I don‟t think we have many... ...I don‟t personally keep them particularly 
innovative, they tend to target to what pharmacist are used to using, so they have 
made the program very simple, very basic.” 
 
Figure 18 presents typical characteristics found in the qualitative analysis which 
stimulated innovations in IT development in community pharmacy. According to 
the interviewees, the stimuli for IT development to support medication 
management in community pharmacies were: Patient Safety; Support for a New 
Service Model; Patient Care Responsibilities; International Trends; Business 
Ideas of a Commercial Company; Legislation to Enhance Electronic Services; 
Low Profits for Pharmaceuticals; and Consequence of Another Innovation. Most 
interviewees reported patient safety as the catalyst for IT development, and 
electronic prescribing was the most often mentioned innovation to address patient 
safety. Patient care orientation emerged as an international trend that was 
pushing new services whose performance required IT support. Alternatively, 
several experts mentioned economic pressures as a driving force for IT 
innovations. Some reported patients‟ healthcare needs, such as smoking 
cessation, as initiators. 
 
“...there has been the decision somewhere that either there will be payment for 
service that some is developing the structure or program that will deliver that 
service... They don‟t seem to be the developing program to help people work 
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through the process. In the ones I have seen, the IT decision is driving the change 
rather than the change [needs] driving the IT.” 
 
Many of the innovations mentioned by the experts actually lacked research as a 
starting point. Less than half were developed from systematic research or even 
pilot research. One interviewee mentioned research in general: there is lots of 
research on large-scale development projects concerning health information 
technology, electronic health records including electronic prescribing and 
integration of the health care providers‟ IT systems. Some experts were unaware 
of explicit research initiatives. In most of the IT development processes described 
by the experts, the coordinator of the process was the government, and only in 
few processes it was a private company. The development processes had taken 
from 5-6 to even 25 years. Leadership was mentioned as a very important factor 
and lack of leadership had been a problem.  
 
“The will of the politicians has been that the projects start, but there has not 
actually been any coordinator and this is the first big problem of the whole 
project.” 
 
Only one expert described the development process as team work, and this 
respondent noted a governmental role. In this process there was cooperation 
between the technologists and the pharmacists who defined the software 
functionalities needed in the pharmacies. Some of the innovations described by 
the interviewees were still in the development process while others had been 
commercialized and were being sold to users.  
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Figure 17 Key community pharmacy IT innovations according to the study participants 
(n=14).   
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Figure 18 Key features of community pharmacy IT innovation development processes 
compared to the Rogers theory of Generation of Innovations (Rogers 2003). 
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Many of the interviewees seemed to have a critical attitude towards commercial 
companies and emphasized the role of the national governments in IT projects. 
However, a few noted an innovation which had been developed as a public 
project led by the government, but was commercialized and delivered by private 
providers. Interviewees were queried as to whether the IT innovation‟s diffusion 
process had been planned and organized. This was a difficult question for most of 
the respondents. One described the matter as a leadership issue spanning 25 
years of attempts to organize the process. One stated that the diffusion process 
was not organized at all, but occurred organically. Interviewees also described the 
users‟ adoption of the innovation. Some thought users were receptive to the 
innovation. Only one had experience with Rogers‟ adopters‟ taxonomy: 
 
“There has been a big variation... you know you have these early innovators 
and the laggards. In almost every pharmacy you find these.  One very important 
thing is the attitude of the pharmacy manager, if he or she finds it important or not. 
And also to have coaches, fire soldiers, someone who really fond of and enjoys 
and finds it very important to do something, is enthusiastic and committed.” 
  
Consequences of IT innovations were systematically evaluated in only a few 
cases; most of the opinions were based on interviewees‟ own estimations.  
According to users‟ feedback, some interviewees reported that an IT innovation 
had met the needs and expectations of its users and had improved quality of care 
or patient safety. Some interviewees were also satisfied with an innovation, but 
felt that pharmacists always want more to be done to support pharmaceutical 
services in community pharmacies. One interviewee could not discuss benefits of 
an innovation, as there had not been evaluative research on it. Another thought 
that an innovation has not met the needs and expectations of its users or 
improved the quality of care. However, interviewees could clearly see that 
innovation stimulated further innovations. The following example describes how 
Medication Review led to other innovations:  
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“...Most of the pharmacists can tell you about the community services, they 
understand that. So, if you look the time before home medication review (HMR), it 
really started with residential care and then it went to HMR then it went to drug 
information then it went to disease state management. So you can see, how the 
innovation over time is spreading.” 
 
Interviewees were asked to identify barriers to innovation and practices that 
supported innovation. Barriers included: Funding; Priorities Set by the 
Management; Technical Issues; Market Competition; and Privacy Protection. 
Practices facilitating innovation included: Good Management; Attitude and Will; 
Funding; Good Quality of the Technical Solutions; Information; and Collaboration 
Between Organizations. The interviewees were also asked to identify issues that 
should be taken into account in the development of new IT systems. Some 
thought that the system should be simple and modular so that new functionalities 
could be added. Others believed the most important element would be to listen to 
end users during the development process. A good consultation process was also 
mentioned, as was research to assess the effectiveness of new technologies for 
improving appropriateness of drug use before a system‟s implementation.  
 
“We have to go forward just to decide when and how to do it. And then all the 
barriers and strengths are to show up and of course on the bottom line people 
say: “Well, it is a good idea, but we cannot do it for several reasons. ... So it is part 
of leadership here, it is part of making the vision real. But people will have to do it! 
So it is mobilizing the innovation.” 
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10 SUMMARY OF KEY FINDINGS 
 
A summary of key findings of this study is presented in a Figure 19. Finnish 
independent community pharmacy owners gave priority to logistical functions and 
also to those functions related to medication information and patient care. The 
managers and staff pharmacists have different views of the importance of IT 
functions, reflecting their different professional duties in the community pharmacy. 
This indicates a need to involve different occupation groups working in community 
pharmacies in planning the new IT systems. A majority of the international experts 
shared the vision for community pharmacy adoption of a patient care orientation; 
supported by IT-based documentation, new technological solutions, access to 
information, and shared patient data. Opportunities to achieve this vision included 
IT solutions, professional skills, and inter-professional collaboration. Threats 
included costs, pharmacists‟ attitudes, and the absence of IT solutions. 
Community pharmacy IT innovations were rare, which is paradoxical because 
owners‟ and staff pharmacists‟ self-perception of their innovativeness was 
indicated to be high. Community pharmacy IT systems development processes 
usually had not undergone systematic research for needs assessment before 
development or evaluation after implementation, and were most often coordinated 
by governments without subsequent commercialization. Specifically, community 
pharmacy IT development lacks research, organization, leadership and user 
involvement in the process.  
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Figure 19 Conclusion based on the results. 
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11 DISCUSSION 
11.1 Finnish community practitioners needs for IT system 
 
Finnish independent community pharmacy owners have an economic 
responsibility for the company and also are responsible for designing and 
financing pharmacy services, and the IT system supporting them. Thus, their 
professional and business visions and strategies are crucial for development and 
implementation of IT systems. They rated IT applications supporting logistics and 
performing basic cognitive pharmaceutical services, such as providing patient 
counseling, drug-drug interaction checks and medication reviews equally highly. 
Survey respondents gave high priority to those features of a new IT system that 
supported logistics. Such IT systems‟ features support managers in optimizing 
stock control and are key components of good business planning. Efficient stock 
control is critical to financial viability, particularly under the pressures to decrease 
the national drug budget.  
 
Respondents rated patient care features as highly as those features related to 
logistics, suggesting that they are committed to the pharmacy profession and not 
only a business strategy for community pharmacy. Female pharmacy owners 
considered features related to cognitive pharmaceutical services somewhat more 
important than did their male colleagues. Similar gender related differences have 
been reported in Canada, where the female pharmacy managers spent more time 
in direct patient contact, indicating the importance they placed on a service 
orientation (Cockerill et al. 1999). Furthermore, Canadian female pharmacy 
managers were more supportive of strategies that promote additional patient 
counseling. Finnish pharmacy owners rated medication safety and related features 
highly, such as computerized documentation of medication and dispensing errors, 
as well as documentation of drug related problems (DRP), e.g., drug-drug 
interactions and adverse drug reactions. This was consistent, regardless of the 
pharmacy‟s size or the owner‟s age or gender. They also gave high ratings to tools 
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such as brief and comprehensive medication reviews. These findings indicate that 
pharmacy owners are aware of the importance of medication safety although they 
may not currently have any actual documentation and follow-up tools.  
 
In the second survey study (II) the reference group was included: data of the 
community pharmacy owners and the M.Sc. pharmacists working as managers 
which was combined and compared with data of B.Sc. pharmacists working 
mainly in direct customer contact with customers. The features related to access 
to databases and facilitating disease management, such as asthma management 
and smoking cessation, were ranked significantly higher than owners by staff 
pharmacists. They also expressed a need for a national online network for 
pharmacists, who are specially trained contact persons to treat and prevent 
Finland‟s most common major chronic diseases in community pharmacies. 
Community pharmacy owners strongly supported IT features related to pharmacy 
management processes. The study results indicate that pharmacists in different 
occupation groups have different preferences with regard to the importance of IT 
features, depending on their duties in community pharmacies. This indicates that 
if the perspectives of pharmacists working in actual customer service are not 
taken into account it might misdirect IT application design with regard to limiting 
features essential for cognitive services.  
 
The study results indicate that a high importance was given to applications which 
were familiar to the users. The Bachelors were not able to comment on the 
importance of the features they were not familiar with, such as financial 
management. Similar findings have been reported in a study concerning 
community pharmacists‟ attitudes towards medication management (MTM) 
services (MacIntosh et al. 2009). The key factor was the familiarity with the 
services whether pharmacists chose to contract to provide MTM services. The 
challenge for the future community pharmacies will be combining the cognitive 
aspects of pharmaceutical care and the economic aspects for profitable business. 
The results of our study indicate that there is a need for taking notice of different 
occupation groups‟ hopes while planning the new IT systems for community 
pharmacy settings. Community pharmacy practitioners who work with different 
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tasks have also varied and limited views of the It needs for all aspects of 
pharmacy operation. This study provides insight into potential needs of a new 
IT system that have the strategic priority among pharmacy managers and staff 
personnel in Finland. An iterative developmental process of community 
pharmacy IT systems development will include practitioners‟ needs and will 
facilitate their adoption. The development of IT systems and applications to 
meet the demands of pharmacists with different duties in the community 
pharmacies will be crucial to success in the future. 
 
In European Union (EU) countries, the directives, regulations and decisions of the 
EU guide the development along with the national laws and standards (Wahlroos 
2003, Väänänen 2008). In Finland, community pharmacies‟ main functions are to 
ensure an adequate supply, and safe and appropriate use of medications, by law 
(Medicines Act 395/1987). However, there are no standards for the quality of 
dispensing, as well as patient care and pharmaceutical care services in the 
Finnish community pharmacy practice except with regard to medication review 
(Leikola et al. 2009). Because Finnish community pharmacy owners have the 
responsibility of providing services, they can choose whether to invest in the IT 
systems supporting professional services, such as interaction screening program, 
or not. As a result polarization has increased also in Finland (Kansanaho et al. 
2005, Tippa Project 2005): some community pharmacy owners are committed to 
develop professional services while some are not. International Pharmaceutical 
Federation (FIP) has suggested that in order to promote the main elements of 
Good Pharmacy Practice (GPP) national standards are essential (FIP 1997): 
 
“For each of the four main elements of GPP, national standards covering processes 
and necessary facilities should be established and promoted to the profession.” 
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11.2 The future of pharmacy practice – visions, concerns and 
strategies 
 
The experts in the international strategic study represented their own countries with 
different national health care and IT systems. Despite their different backgrounds, 
the results indicate similar opinions and a common vision for developing IT systems 
to support the provision of patient care service in community pharmacies. The 
interviewed experts shared the expectation that community pharmacies will be 
more involved in the provision of patient care services and their consultative role 
will increase. This was in line with international trends and what is happening in the 
United States (US) and Europe (Christensen and Farris 2006, Hughes et al. 2010). 
The opinion of the experts was that IT applications are necessary tools in the 
provision of patient care services, and an essential component in the 
implementation of increased professionalism in community pharmacy. IT was seen 
as particularly necessary in facilitating access to information such as clinical patient 
data, guidelines, and evidence-based data needed in patient care. Community 
pharmacy IT systems are most likely to be successful in optimizing patient care if 
they are developed in conjunction with other health-related IT applications. 
Improving standardization of systems across multiple institutions may be important 
for the wider adoption of IT to prevent medication errors (Agrawal 2009). 
 
Although there was consensus among the interviewed experts regarding the 
desired direction of strategic development they raised concerns about the future. 
These concerns revolved around increasing commercialism and its corresponding 
influence on the functions and public image of community pharmacy. The challenge 
of integrating patient care services into current and emerging business models has 
been described in the literature (Feletto et al. 2010). In this respect, some of the 
interviewed experts were worried about the differentiation between community 
pharmacies. Some pharmacies will focus their business on increasing dispensing 
and sales, while other pharmacies may choose to develop their business by 
strengthening their professional role through the provision of pharmaceutical care 
service. This differentiation has been reported previously (Doucette et al. 2006).  
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The impact of political decisions being imposed on the pharmacy profession was 
seen as a concern by the experts. This occurred in Iceland, which was the first of 
the Scandinavian countries to make dramatic regulatory changes in the mid-1990s, 
which resulted in a deregulated community pharmacy system (Morgall and 
Almarsdottir 1999). Political decisions may also strongly influence the economic 
viability of community pharmacies. The interviewed experts perceived costs and 
needing to maintain economic viability as a threat to strategic development of IT 
applications. Thus, they called for sustainable reimbursement to pharmacies to 
support provision of pharmaceutical care services and IT applications needed to do 
it. In a national survey Finnish community pharmacy owners gave high priority to 
those features of a new IT system that were supporting logistics. Efficient stock 
control is critical to financial viability. Different remuneration models are possible, 
but the political will to change must be preceded by pharmacists formulating an 
explicit and proactive strategy to demonstrate the added value and the quality of 
patient care services (Bernsten et al. 2010). This kind of evidence is needed to 
inform IT development and for justifying allocation of community pharmacists‟ time 
to service provision. Time constraints were mentioned in the current study as a 
threat, and this was consistent with several previous studies of barriers to service 
provision in community pharmacies (Montgomery et al. 2007, Blake et al. 2009, 
Blake and Madhavan 2010, Kritikos et al. 2010, Paydyal et al. 2010). 
 
The interviewed experts referred to professional skills and attitudes of community 
pharmacists as both weaknesses and opportunities. Pharmacists‟ resistance to 
change were perceived as a weakness, but their interest in patient-oriented care 
was seen as an opportunity. The new generation of pharmacists and their 
increased professional skills were seen as opportunities. Professional skills were 
associated with both IT use and provision of patient care service. Underuse of the 
current IT systems was seen as a weakness. To prevent medication errors using IT 
it is not only the technological capabilities of the IT that are important but also their 
implementation and use (Agrawal 2009). Previous studies have also reported that 
the lack of skills among community pharmacists may limit the implementation of 
new technologies to provide patient care (Latif and Boardman 2008). Additional 
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research is needed to assess theoretical and practical competency needs of 
community pharmacists. 
 
Countries involved in our study had similar intent, but the poor quality of the 
current IT systems and limited resources to develop more sophisticated systems 
were seen as problems. One way to get more resources is to enhance 
international cooperation between parties involved in community pharmacy IT 
development.  Even though the international cooperation was identified by the 
interviewees as being quite low, limited to participation in congresses and 
symposiums instead of having actual joint IT development projects, no one 
mentioned international cooperation as a strategic opportunity. In 2007, the 
French government invited The Office of the National Coordinator for Health 
Information Technology (ONC) from the US to collaborate with the European 
Union in conducting a conference International Challenges in eHealth and Health 
IT: Managing Toward a common Goal, held in Paris in 2008 (Friedman et al. 
2009). Three areas were identified as highest priority for international 
collaboration in future: 1) Health data security ; requiring new policies and 
technology applications to managing access and governing sharing health data 2) 
Ensuring healthcare professionals‟ acceptance of HIT tools, measuring the actual 
usage of the tools would better inform and guide policy development 3) 
Interoperability; establishing standards and clear guidelines for their 
implementation. The implementation of these recommendations requires strong 
leadership of the national governments and health care businesses (Friedman et 
al. 2009). There still  is lack of standardization concerning software interfaces to 
enable communication between systems; pharmacists need communication 
standards to electronically communicate with the physicians, hospitals, patients 
and caregivers (Webster and Spiro 2010). Cooperation can generate more ideas, 
more opportunities, more alternatives and more ways for implementation when 
new IT systems for community pharmacies are developed. International, 
cooperative IT development can also reduce costs. E.g., the FIP Pharmacy 
Information Section could provide a platform for discussion and more coordinated 
actions in IT development. 
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11.3 Paradox between innovativeness and innovations  
 
According to this study, the processes for generating community pharmacy IT 
innovations only partially follow the six phases described by Rogers‟ theory. The 
most neglected phase was performing systematic research before proceeding to 
IT system development. The next common gap was with evaluation of results 
after implementation. Lack of research in the process was more evident when the 
entity responsible was a private company. This failure to perform a systematic 
needs assessment may lead to a very limited understanding of the user„s 
perspective. This inadequate understanding may then influence the evolution of 
subsequent innovations (Rogers 2003).  
 
A majority of the community pharmacy IT development processes described by 
the experts were coordinated by governments and lacked commercialization as of 
the time of this study. Although there are private business solutions for community 
pharmacy services in most of the countries involved in the study (Rigby 2004, 
Jackson et al. 2006, McMahan 2008), the interviewees emphasized the role of 
national governments in the development phase. National governments‟ 
development processes though generally organized and controlled also seem to 
be slow and bureaucratic. The expert interviews attribute this to a lack of 
leadership and funding throughout the innovation process. Lack of leadership 
subsequently led to development processes that were not well-planned and 
implemented. Similar leadership challenges were found with government-led 
processes in the adoption phase. Our findings are consistent with previous 
implementation studies of community pharmacy residency programs in the US 
(Schommer et al. 2010), and electronic health records systems in multiple 
countries (Deutsch et al. 2010). These studies have concluded that strategic, 
organizational and human challenges are more complex and more difficult to cope 
with than is the technology alone (Deutsch et al. 2010). It may be possible that 
governmental coordination correlate to the present situation in which there have 
been few innovations in community pharmacy IT. The study results suggest that 
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the pharmacy profession should assume more responsibility for development of 
the IT tools that support their practise.  
 
This study indicated that community pharmacists in Finland and in the Netherlands 
have a similar willingness to adopt innovations as they are subjectively measured 
by Rogers‟ instruments. Their self-reported innovativeness is much higher than that 
of populations included in Rogers‟ classical studies, which may indicate a real but 
as yet unrealized difference in innovativeness favoring community pharmacists. 
Rogers‟ theory and his adopters curve (Figure 11) are based on observational data 
gathered in the 1950s (Rogers 1958).  Both community pharmacists‟ studies are 
based on surveys that assess self-perception of innovativeness. Another 
explanation for the difference in findings between Rogers early work and the 
present study may be the time frame; it is possible that nowadays change occurs 
faster and the social pressure to adopt innovations is higher. As a consequence, 
the bell shape of the adopters curve would move in the direction of the innovators 
category, even if the theoretical underpinnings do not change. This specific 
development should be explored with broader populations than community 
pharmacists alone; to see if this has been shifting the adopter curve.   
 
According to this study, both Finnish pharmacy owners and employed pharmacists 
define themselves as innovators who are willing to adopt IT innovations. However, it is 
a paradox that the actual rate of IT systems innovations has been slow in Finnish 
community pharmacies. Is this a consequence of authorities having strict control over 
community pharmacies, resulting in more constrained resources being available for 
implementing innovative IT systems and programs? The currently implemented 
Finnish IT systems for community pharmacies‟ professional needs have been mostly 
developed in the 1990s. The existing software does not contain modules devoted to 
medication safety, nor do ones to support cognitive pharmaceutical services, even if 
the need for such features has been recognized. However, development of community 
pharmacy IT is also a health policy issue as well a leadership issue. Collectively, these 
forces and professionals provide the driving force, strategy and coordination required 
to achieve or delay the development and implementation of innovative IT systems. 
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11.4 Methodological considerations 
 
None of the study methods are absolutely accurate or non-biased. In this study, 
method triangulation was used to strengthen the study methods employed and to 
ensure the comprehensiveness of the study (Pope and Mays 1995, Smith 2002). 
Triangulation was found to be particularly useful for the following reasons: 1) the 
use of quantitative methods (STUDIES I-II) enabled receiving nationally 
generalizable results, 2) quantitave studies (STUDIES I-II) enabled comparison 
between different occupational groups working in community pharmacies, 3) the 
quantitative perceived innovativeness (STUDY IV) enabled comparison with 
earlier studies in Finland, The Netherlands and in the US, 4) the qualitative 
methods (STUDIES III-IV) provided deeper understanding of the visions, 
strategies and the IT innovations development processes concerning IT to support 
medication management. 
 
Scientific rigour and quality of the research are assessed in terms of reliability, 
validity, and generalizability of the results (Smith 2002). Reliability relates to the 
repeatability and internal consistency of the research. Validity refers to the extent 
to which an instrument or method measures what it is supposed to measure. 
Validity can be divided into external and internal validity (Tuomi and Sarajärvi 
2003, Roberts and Priest 2006). Internal validity could be increased by piloting the 
questions (content validity), comparing the questionnaire with other validated 
measurements of the subject (criterion validity) and by demonstrating the 
relationship between the concepts under study and the theory (construct validity). 
Factors that could decrease the validity include small sample size and errors 
during different study periods. The generalizability (referred also as external 
validity) is concerned with the extent to which the findings can be applied more 
widely to other settings or populations. The following section discusses the 
reliability, validity, and generalizability of the studies I-IV.  
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11.4.1 Quantitative studies I-II 
 
Surveys are widely used to obtain data from a large group of people and to 
generalize the findings to larger populations (Smith 2002). This method has been 
used for gathering information concerning views and attitudes which are often 
seen as determinants of practice and indicators of the feasibility of change. Most 
surveys focus on issues that are important to a profession and its development. 
Usually, the object of the survey is to provide information about the change and to 
facilitate its progress (Smith 2002).   
 
These sub-studies were based on data received from the national surveys 
conducted in Finland. The survey studies were targeted to all Finnish independent 
pharmacy owners (n=580) (STUDY I) and staff pharmacists with Bachelor‟ (B.Sc.) 
and Master‟s (M.Sc.) degree working in Finnish independent community 
pharmacies (n=1709) (STUDY II) with a registered and valid e-mail address and 
who had given permission to their professional associations to make available 
their e-mail addresses for research purposes. The survey instrument was 
customized to be applicable to the Finnish pharmacy system and, therefore, the 
results may have limited direct generalizability to other countries. Both surveys 
applied the same survey instrument. The survey instrument was piloted in a 
convenience sample of 14 pharmacy practitioners for the face validity 
determination and the comprehensiveness was further refined. The IT system 
features included in the survey instrument reflect the Finnish health care and 
medication management system could you omit this phrase. Thus, the survey 
instrument may not be applicable to other countries as such. This also limits the 
generalizability of the results to other countries and systems. 
 
A total of 308 responses were received from the pharmacy owners (response rate 
53%) and 373 responses from the staff pharmacists (response rate 22%). Of 
these, 34% had a M.Sc. degree (n=128), 63% had a B.Sc. degree (n=234) and 
3% were pharmacy students (n=11). The most significant limitation of this 
nationwide study is the low response rate and the non-response bias caused by it, 
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particularly among staff pharmacists. The data available did not enable the 
analysis of respondents vs. non-respondents. It is possible that those who were 
less interested in IT were less likely to respond. It is widely accepted that survey 
data may be affected by the characteristics of respondent (e.g. knowledge; 
experience; and motivation). All respondents may not interpret the questions as 
intended by the researcher. On the other hand, the low response rate among staff 
pharmacists may be partly due to the data collection via the Internet. Our previous 
studies have shown that Finnish community pharmacists are not used to 
responding to Internet surveys and it has been typical that the response rate is 
20-30% even after 1-2 reminders. The normal response rate for mail surveys 
among community pharmacists has been 50-60% (Kansanaho et al. 2004, 
Kansanaho et al. 2005, Puumalainen et al. 2005, Teinilä et al. 2008). It is also 
noteworthy that the data were collected by a mail survey among community 
pharmacy owners (response rate 53%), but the survey instrument was the same.  
 
The characteristics of the respondents were similar to those of the target 
population especially by age and gender, which indicates achieved 
generalizability nationally. The staff pharmacists with the M.Sc. degree were more 
active responders than B.Sc. pharmacists. Also the owners and pharmacists 
working in large pharmacies were more frequent responders. Even if the response 
rates were quite low, particularly among staff pharmacists, the shapes of the 
curves concerning perceived innovativeness followed the bell shape reported by 
Rogers in 2003. However, the pharmacists‟ curves were more towards the 
innovator than towards the laggard, which was slightly different from Rogers 
theory (Rogers 2003), but more similar to the results of the earlier studies (Pronk 
2002, Saario 2005) conducted in the Netherlands and Finland. 
11.4.2 Qualitative studies III-IV 
 
The qualitative semi-structured interviews (STUDIES III-IV) were conducted to 
explore the experiences of internationally recognized experts (n=14) in relation to 
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their visions; and strategies (STUDY I); as well as development and 
implementation of IT (STUDY II) to support medication management in community 
pharmacy setting. The method was selected because it allowed the interviewer to 
re-word, re-order and clarify each question based on the responses of the 
participants (Tong 2007). The study was designed in accordance with the RATS 
guidelines for conducting and reviewing qualitative research (Clark 2003).  
 
The interview guide was pre-tested for face-validity by conducting one pilot 
interview. No modifications were deemed necessary. Data from the pilot interview 
were not included in the final analyses. A purposive sampling strategy was 
employed. The final sample size was defined by the point when data saturation 
occurred (when no new categories, themes or explanations emerged). Qualitative 
research studies do not necessarily require a large random sample because 
generalizability is not the objective (Marshall 1996). Therefore, the results are not 
intended to be generalized. Saturation of the data was achieved, which indicates 
that a comprehensive description of the phenomena studied was possible to 
construct. However, including more experts may have increased the richness of 
the data and reliability of the findings. Furthermore, the results are based on 
findings from developed countries within well-organized healthcare environments. 
The development needs may be different in developing countries and countries 
with different kinds of health systems. The part II of the interview study (STUDY 
IV) was intended to gather knowledge about the community pharmacy IT 
development processes to support patient care services. One limitation is that 
some of the respondents could not give all the information needed, because they 
did not know all the details of the processes.  
11.4.3 Ethical considerations 
 
All the study procedures were conducted in accordance with good ethical practice 
and when relevant, in accordance with the World Medical Association Declaration 
of Helsinki. Support for conduct the study was sought and obtained from the 
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Association of Finnish Pharmacies (mailing costs for the survey study for the 
Finnish owners and the participation of the FIP congress in China for conducting 
the interview study). The identities of individual survey respondents were not 
recorded as part of the data collect processes. Reading the cover letter and 
returning the completed survey was considered to be informed consent for 
participation in the survey. Prior to the interviews, potential participants were 
invited to participate by e-mail. The participants were well–informed about the 
study procedures, both orally by the researcher and with a written information 
sheet. In this information sheet, participants were informed that the interviews will 
be tape-recorded and confidentiality was emphasized. A consent form was signed 
by all participants at the beginning of the interview. Participants could refuse to 
participate at any time. The data were processed confidentially and the results are 
expressed so that individuals cannot be identified.  
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12 CONCLUSIONS 
12.1 Implications in practice  
 
Based on the results of the study, the following conclusions can be drawn: 
 
1. In strategic planning for a future IT system in community pharmacies, 
pharmacy owners ranked logistical functions most highly but included 
features that would facilitate cognitive pharmaceutical services and patient 
care in that category. The results of this survey indicate pharmacy owners‟ 
commitment to implementing cognitive pharmaceutical services and health 
policy goals along with further development of their business capabilities. 
This dual professional and business orientation exists despite their 
responsibility for financing development of IT system. 
 
2. The managers and staff pharmacists have different views on the 
importance of IT features, reflecting their different professional duties in the 
community pharmacy.  A high priority was given for the features familiar to 
the users and needed in their daily practice. This indicates the need for 
involving different occupation groups in planning the new IT systems for 
community pharmacies. An iterative developmental process will include 
practitioners‟ needs and will facilitate adoption. 
 
3. Those responsible for IT development in community pharmacy sector 
should create long-term IT development strategies that are in line with 
community pharmacy service development strategies.  
 
4. The development processes for IT and related community pharmacy 
innovations do not entirely follow theoretical framework on the diffusion of 
innovations. Specifically, community pharmacy IT developments lack 
research, organization, leadership and user involvement in the process. 
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5. Community pharmacy IT innovations were rare and focus on limited areas. 
This is paradoxical because community pharmacists‟ self-reported 
innovativeness was perceived to be high. 
12.2 Further research 
 
More research should be focused on strategic planning of community pharmacy 
services and related IT applications within a wider health system context. The 
pharmacy profession‟s own visions and strategies concerning patient care 
services should guide this research and development. Despite the importance of 
these services and the supportive IT systems, there has been only little research 
in community pharmacies setting on the operation of patient care services and 
how IT is used in providing these services. More research should focus on 
assessing theoretical and practical competency needs of community pharmacists 
with a strategic perspective. Diffusion of innovations framework could provide 
systematic guidance for future projects to ensure that potential innovations are 
based on a sufficient understanding of the pharmacy practice problem that they 
are to solve. 
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APPENDICES 
Appendix 1.  The potential features for the future community pharmacy IT 
systems included in the study. 
      
Drug information and patient counseling (11 items) 
Online national reference book 
A checklist-type drug information database to support medication counseling  
Drug-drug interaction program 
Patient‟s health profile 
National current care guidelines 
Pharmacy protocol for medication counseling 
Link to a health information portal 
Electronic information from pharmaceutical companies 
Self-medication guidelines 
Demonstration program for drug administration technique 
Hospital discharge summary         
Medication safety (10 items) 
Documentation of dispensing errors 
Documentation of prescribing errors 
Documentation of drug related problems 
Documentation of adverse drug reactions 
Documentation of drug-drug interactions 
Documentation of medication misuse 
Documentation of adherence 
Electronic notification of product failure 
Reporting system for the substandard products to the pharmaceutical wholesaler  
Electronic notification of ADRs to the National Agency for Medicines    
Interprofessional collaboration (10 items) 
Online prescription refill 
Medication availability request from physician 
Reporting the presciptions to the physician 
Prescribing feedback to the physician 
Online contacts to the physicians 
Online contacts to the age care facilities 
Online reimbursement service 
Online contacts with the insurance companies 
Medication review integrated to other healthcare IT systems  
National online network between disease management pharmacists    
Pharmaceutival services (27 items) 
ePrescribing  
Medication compounding program 
Pricing program for extemporaneous products 
Brief medication review 
Comprehensive medication review 
Rehabilitation contract for drug addiction 
Methadone program 
Automated dose dispensing 
Disease management program for asthma 
Peak Flow measurement (documentation for follow-up) 
Disease management program for diabetes 
Smoking cessation program 
Patient counseling appointment program 
Online drug order from customer to the pharmacy 
Checking the customer‟s medicine cabinet 
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Home delivery of medication 
Healthy lifestyle service concepts 
Following and optimizing the customer‟s costs of the medicines 
Patient‟s medication cost report 
Patient‟s health information record 
Following the laboratory test results related to the medication 
Medication counseling by telephone 
Medication counseling by internet 
Product reorder alert based on customer 
Remindments of medication by e-mail or text message 
Measure and vaccination services 
Online purchase of non-prescription items       
Pharmacy’s internal processes (31 items) 
Financial management (7 items) 
Accounting  
Budgeting 
Salary calculations 
Credit control 
Short-time financial planning 
Ability to generate electronic invoices 
Financial forecasts 
Personnel (10 items) 
Staff roster  
Daily job responsibilities 
Vacation roster 
Log book for continuing professional development 
Tool for staff communication 
Managing staff expertise of personnel 
Staff workflow 
Recruitment 
Orientation 
Termination of an employment 
Sales and marketing management (8 items) 
Space management 
Marketing  
Calendar for campaigns 
Planning the assortment 
Customer analyses 
Complaints handling 
Electronic cold facilities monitoring  
Electronic forms for pharmacy 
Stock (6 items) 
Ability to generate orders based on sales 
Tracking product expiry 
Managing stock holding 
Following the delivery assurance of other companies 
Updated product information for pharmacists 
Analysis of stock moving speed         
 
 
  
  
 
 
 
169 
Appendix 2. 
 
INNOVATIVENESS 
 
Which of following choices describes best your own attitude to the changes and 
new function models? 
 
1. I want to be involved in testing and developing immediately 
2. I take the innovations in use quicker than average and I am pleased to tell 
about them to other people 
3. I do not take the innovations in use until the benefits are shown 
4. I need time to considering and support 
5. I do not wish changes, I am happy with the situation nowadays and I like 
routines 
6. Do not know 
  
  
 
 
 
170 
 
Appendix 3. 
 
Community Pharmacy Information Technology Systems –  
Visions and Innovations 
 
Part I 
 
DEMOGRAPHIC DATA 
 
Please describe your special expertise areas in information technology (IT), with 
special reference to the community pharmacy and medicine management 
systems.Please describe briefly your professional history with IT and your 
contribution to the systems, specifically in community pharmacies and medicines 
management. 
 
 National/international experience 
 
VISIONS FOR THE FUTURE COMMUNITY PHARMACY SERVICE AND IT 
 
What is your vision for the community pharmacy services? 
 
 What are the key functions for the community pharmacies in relation to the 
health care and how could IT support that work? 
 In a) 5 or b) 10 years‟ perspective? 
 Which factors and opportunities can facilitate the vision to come true? 
 Which would be the barriers or threats in the process of the vision to come 
true? 
 
What is your vision for the community pharmacy IT system in the future? 
 
 In a) 5 or b) 10 years‟ perspective? 
 Which factors and opportunities can facilitate the vision to come true? 
 Which would be the barriers or threats in the process of the vision to come 
true? 
 
CURRENT SYSTEMS 
 
What are the strengths and weaknesses of the current IT systems? 
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Part II 
 
GENERATION OF INNOVATIONS 
 
What led to the development process of the innovations you described? 
 Patient safety/regulatory affairs/medical issues/business interests  
 
Was there any research before the development process started? 
 
Please select one most important innovation and describe briefly the development 
process. 
 
 What was the driving force of its development process? 
  Who was the coordinator of the development process? 
 How much the health policy was related to its development process? 
 How long did the development process take? 
 Were there any barriers in the development process? 
 In general, which factors facilitate or drive development of IT concerning 
medicine management and pharmaceutical care services in community 
pharmacies? 
 
Was the above discussed most important innovation commercialized, or will it be? 
 
How did the users adopt the innovation? 
 
 Was it easy to get the users to adopt the innovation? 
 Were there any barriers in the diffusion process? By diffusion I mean… 
 Which factors can facilitate the diffusion process? 
 How was the diffusion process organized? 
 
What are the consequences of the innovation: has it met the needs and 
expectations of its users? Has it improved quality of care or patient safety?  
 
 Has the innovation brought any further innovations? 
 
On the basis of your expertise, could you give some general recommendations 
what kind of things should be taken into account when a new IT system is going to 
be developed for the community pharmacy? 
 
How the health policy goals should be considered in the development of 
community pharmacy IT? 
 
Can you identify further needs for innovation development in the community 
pharmacy IT systems? 
 
Do you have any other comments? 
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